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ABSTRACT 
 
 Bile acids (BAs) are bioactive molecules that are crucial for the absorption of fat-soluble 
nutrients and regulation of host metabolism, including glucose, lipid, and energy homeostasis. BAs 
are synthesized in the liver and are further metabolized by microbiota in the gut. Previous studies 
have shown that an alteration of gastrointestinal microbiota, referred to as dysbiosis, can alter the 
bile acid profiles. This aim of this project was to identify and characterize Clostridium hiranonis, 
a bile acid 7α-dehydroxylating bacterium from canine feces, and to study the association between 
C. hiranonis and secondary bile acids (SBAs). 
 Firstly, this study evaluated the fecal microbiome of dogs with exocrine pancreatic 
insufficiency (EPI) based on 16S rRNA sequencing. The fecal microbiota of dogs with EPI was 
different when compared to healthy control dogs. In dogs with EPI, the bacterial families, 
Lachnospiraceae and Ruminococcaceae were decreased, while Lactobacillus, Bifidobacterium, 
and Enterococcus were increased in dogs with EPI. At the species level, Blautia producta, 
Clostridium hiranonis, Faecalibacterium prausnitzii, Ruminoccocus gnavus, and Collinsella 
stercoris were decreased in dogs with EPI.  
Secondly, this study isolated, identified, and characterized C. hiranonis from canine feces. 
The canine isolates were similar to the reference strain C. hiranonis DSM 13275 based on 
morphological, biochemical, and fatty acid profiles. Based on whole genome sequencing results, 
these isolates possess genes for the enzymes choloylglycine hydrolase, and bile acid 7α-
dehydratase, which are essential for deconjugation and bile acid 7α-dehydroxylation of primary 
bile acids. 
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Finally, this study examined the correlation between C. hiranonis and SBAs in canine fecal 
samples. Results show that C. hiranonis and SBA concentrations are significantly correlated in 
canine feces. The ROC analysis showed that the fecal abundance of C. hiranonis can be used to 
discern between normal and low fecal SBAs with a sensitivity of 88% and specificity of 90% in 
dogs. In conclusion, this is the first study to isolate and characterize C. hiranonis from canine feces 
and to find a significant correlation between SBA concentrations and abundance of C. hiranonis 
in canine feces.  
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GPRs  G-protein coupled receptors 
IBAT Ileal bile acid receptor 
IBD  Idiopathic inflammatory bowel disease 
IBS Irritable bowel syndrome 
KEGG  Kyoto Encyclopedia of Genes and Genomes 
LCA  Lithocholic acid 
LEfSe  Linear discriminant analysis effect size 
MCA  Muricholic acid 
OTUs Operational taxonomic units  
PBA Primary bile acids 
PCoA  Principal coordinates analysis  
qPCR  Quantitative real-time polymerase chain reaction 
ROC  Receiver operating characteristic 
SBA Secondary bile acids 
SCFA  Short-chain fatty acid 
SCFA Short-chain fatty acids 
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
 
 
1.1 Canine gut microbiota 
1.1.1 Characterization and composition of canine gut microbiota 
Amongst all the different microorganisms that inhabit the GI tract, the bacterial group is 
perhaps the best and most commonly described group of microbes [1]. A metagenomic study by 
Swanson et al.showed that bacteria may represent as much as 98% of all fecal microbiota in dogs 
[2]. Species from the archaeal domain (mostly methanogens) have also been described in the 
canine GI tract and represented ∼1% of all sequences [2].  
The composition and metabolic potential of the bacterial communities differ along the 
length of the GI tract based on physiological and environmental differences [3]. Factors that 
influence bacterial composition are pH, nutrient availability, gut motility, redox potential, and 
host secretions (e.g., gastric acids, bile, and pancreatic secretions) [4, 5]. The bacteria that inhabit 
the gut belong to hundreds of different species. Bacterial abundance increases along the GI tract 
[6]. The healthy bacterial gut microbiota is dominated by obligate anaerobes, especially in the 
colon, that is primarily anaerobic, and provides a nutrient rich environment for intestinal 
microbial colonization [7]. Similar to the major bacterial groups found in humans and cats, the 
predominant bacterial phyla found in the canine gastrointestinal tract are Firmicutes, 
Bacteroidetes, Proteobacteria, Fusobacteria, and Actinobacteria, but there are large differences in 
the relative proportions of these groups in these three hosts [8, 9].  Phylum Firmicutes is 
currently the largest bacterial phylum and contains approximately 200 genera [10]. The majority 
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of the Firmicutes detected in the GI tract belongs to two main groups, the Clostridium coccoides 
group and Clostridium leptum group, also known as Clostridium cluster XIVa and Clostridium 
cluster IV respectively [5]. Both these groups contain members of the genera Clostridium, 
Eubacterium, and Ruminococcus.  The phylum Bacteroidetes consists of three classes, including 
the genera Bacteroides and Prevotella [5, 11]. Other phyla that have been detected in the canine 
GI tract include Spirochaetes, Verrucomicrobia, and Lentisphaera. 
Predominant fungal phyla that inhabit the canine gut include Ascomycota and 
Basidiomycota, while Candida and Nacaseomyces are the predominant genera that have been 
described in the canine gut [2, 12, 13]. 
 
1.1.2 Methods for studying the gut microbiota       
 Culture based methods were widely used to characterize the gastrointestinal microbiota. 
Cultured bacteria are streaked on solid agar media for isolation into pure colonies, after which 
they are identified using various methods. 
Culture dependent methods rely on isolation of the bacteria into pure cultures and then 
studying the morphological characteristics such as bacterial cell size, shape, organization colony 
characteristics (color, shape), staining, and motility. Phenotypic characteristics such as nutritional 
requirements, type of substrates utilized, fermentation products, optimal growth requirements 
(oxygen, pH, and temperature), antibiotic sensitivity and tolerance to various environmental 
pressures (temperature, salinity, pH, pressure, and oxygen) are also used to characterize bacteria. 
Chemotaxonomic methods are culture dependent as well and rely on studying the biochemical 
composition of the cell such as fatty acid composition and whole cell proteins.   
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    Lactobacillus, Bifidobacterium, Eubacterium, Bacteroides, and Peptostreptococcus 
spp. were the most commonly isolated bacterial groups from the human and animal GI tract 
using traditional culture-based methods. Novel culturing methods utilizing microbeads or 
multiplexed solid surfaces are often called as high-throughput culturing approaches. Such 
methods have facilitated the simultaneous single-cell cultivation of a number of bacteria, which 
is essential for studying complicated gut microbial communities. Through the course of time, GI 
microbiota has evolved and adapted to a symbiotic relationship with the host and with each other 
for meeting their metabolic needs, and this poses a challenge in isolating and maintaining a pure 
culture of all the members of the gut microbiota [14, 15]. 
The advent of molecular tools targeting the 16S ribosomal ribonucleic acid (rRNA) gene 
is now commonly used to characterize the gastrointestinal microbiota. Not surprisingly, the 
number of molecularly detected GI tract operational taxonomic units (OTUs) has outnumbered 
the cultivated GI tract species.  
A study using 454-pyrosequencing of 16S rRNA genes, fluorescence in situ 
hybridization, and quantitative real-time PCR (qPCR), evaluated the microbial composition of 
gastric mucosal biopsies from healthy dogs [16]. A median of 36 (range of 18–119) operational 
taxonomic units (OTUs) were detected. The majority of the sequences belonged to the phylum 
Proteobacteria (99.6%), with only a few sequences belonging to the phylum Firmicutes (0.3%). 
The genus Helicobacter spp. was the most abundant genus (98.6 %) within the phylum 
Proteobacteria [16]. 
 
1.1.3 Factors affecting the composition of gut microbiota     
 The mammalian gut microbiota is dynamic and individualistic. Human studies report a 
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large degree of inter-individual variation in the gut bacteria, such that each individual has a 
unique “fingerprint” of bacterial taxa [17-19]. This variation is also seen in dogs (Figure 1). 
Apart from this, gut microbiota is shaped by many other factors such as age, diet, 
microbial exposure, infection and genetic components which affects the gut microbiota 
composition [17].   
Despite the advances in the microbiome field, the mechanisms by which a healthy gut 
microbiome is maintained and how an altered microbiota leads to disease pathogenesis still 
needs to be studied. Dissecting out a distinct microbial and metabolite signature with metabolites 
and diseases has diagnostic as well as therapeutic utility.  
 
1.1.4 Functional role of GI microbiota 
The gut microbiota maintains a beneficial relationship with the host cells. The bacteria 
gain nutrients and energy from host dietary components and shed epithelial cells while 
contributing to the maintenance of metabolic and immunologic homeostasis within the host [20, 
21]. Intestinal microbiota also defends the host from invading pathogens by colonization 
resistance, competition for nutrient substrates and space, and production of antimicrobial 
compounds such as bacteriocins [22, 23] 
The resident flora of the gut mainly derives their nutrients from dietary carbohydrates 
that the host intakes. Bacteria ferment sugars and indigestible oligosaccharides and results in the 
production of short chain fatty acids (SCFA) such as acetate, butyrate, and propionate. These 
SCFAs serve as important energy sources to the intestinal epithelial cells and have 
immunomodulatory effects.  Colonic organisms such as Bacteroides, Roseburia, 
Bifidobacterium, Fecalibacterium, and Enterobacteria act through multiple pathways for the 
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production of SCFAs. For example, Bacteroidetes are able to metabolize complex carbohydrates 
to acetate. Acetate is utilized by butyrate producing bacteria such as Clostridium spp. and 
generate butyrate. Bacteroidetes and some Firmicutes (e.g., Lachnospiraceae) can produce 
propionate from lactate or succinate through the acetylate or succinate pathway, respectively. 
Gut bacteria utilize fiber as growth substrates and produce butyrate. Studies have shown that 
prebiotic administration can result in an increased relative abundance of Bifidobacterium and 
butyrate producing bacteria (e.g.,  Roseburia inulinivorans and Fecalibacterium prausnitzii) 
[21]. This may be due to the ability of colonic Bifidobacteria to metabolize oligosaccharides and 
produce acetate and lactate which can be converted into butyrate by other colonic bacteria 
through cross-feeding interactions [24]. 
The gut microbiota maintains a beneficial two-way communication with the immune 
system of the host and participates in a variety of metabolic processes, which is of mutual benefit 
to the host and the bacteria. Gut microbiota and their metabolites are necessary for maintaining 
the host health status. Commensal microbiota protects the host from invading pathogens [25]. 
The fermentation process produces energy, which supports microbial growth. The microbiota, in 
turn, provides nutrition support for enterocytes [26].  
Currently, there are many studies undertaken that are geared toward understanding the 
functional contribution to the host. Prediction of the functional capability of gut microbiota can 
be understood by metagenomic studies, in which the assembled sequences can be compared to 
reference databases such as Kyoto Encyclopedia of Genes and Genomes (KEGG) and Clusters of 
Orthologous Groups (COG) [27]. Studies have shown that the relative abundance of functional 
categories of metabolic pathways (KEGG) revealed a generally consistent pattern regardless of 
the inter-individual variation of bacterial taxa [19]. 
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Marker gene based metagenomic sequencing is a fast method to understand bacterial 
communities and distribution, based on the reference sequences in databases [28]. Most bacterial 
species of the gut microbiota do not have cultured representatives or complete genomes 
available. Functional input about the community based on 16S rRNA sequencing is imperfect 
since the function is largely strain-specific. Bacterial strains with identical 16S rRNA gene 
sequence will have different gene content, which may contribute to their functional difference 
[27, 29]. Therefore, for linking specific functions and genes to the presence of a bacterial 
species, complete microbial gene sequences and associated functional analysis are needed. 
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Figure 1:  Inter-individual variation in bacterial taxa, while metabolic pathways remain stable in 
the healthy canine gut. Panel A shows the abundance of the predominant bacteria in healthy 
canine fecal microbiota. Panel B shows the functional potential of the fecal microbiota in the 
same healthy dogs. Bar charts were constructed from a 16S rRNA dataset from fecal samples 
from healthy control dogs and baseline samples from healthy dogs before diet and metronidazole 
intervention [30].  
A) 
 8 
 
 
1.2 Bacterial dysbiosis and diseases 
1.2.1 Bacterial dysbiosis 
Élie Metchnikoff first introduced the concept of dysbiosis. However, it was Scheunert 
who first used the term in the microbiological sense in 1920 [31, 32]. Bacterial dysbiosis refers 
to the microbial imbalance in the gut, which may lead to an alteration in the structural and/or 
functional capacity of gut microbiota. Studies have shown that the dysbiosis of gut microbiota 
can lead to an alteration in host physiological processes, resulting in the pathological changes 
attributes to different diseases [33]. Dysbiosis can also be induced in the host by antibiotic 
administration [33-35]. 
Dysbiosis has been linked to diseases such as obesity, diabetes, and autoimmune, allergic, 
and inflammatory infectious diseases, and even to an imbalanced cellular homeostasis which 
may lead to cancer [36]. For example, expansion of intestinal Prevotella copri is strongly 
correlated with disease in patients with new-onset untreated rheumatoid arthritis. In these 
patients, the increase in Prevotella copri also correlated with a reduction in Bacteroides [37].  
Therefore, a dysbiosis pattern with specific changes in the bacterial composition, 
diversity, and metabolic capacity may be investigated as a biomarker for predicting the onset or 
monitoring the disease progression of specific diseases [12]. Currently, the most common 
approach is to study alterations in the composition of the gut microbiota in diseases. Since the 
inter-individual and intra-individual variations in the composition of the gut microbiota are 
significant, it is difficult to establish or define a ‘healthy’ or ‘normal’ microbiota.  It is not 
clearly understood if altered gut microbiota is a cause or consequence of a given disease [20, 21]. 
However, scientists are increasingly employing human-microbiota associated (HMA) mice in 
which a human microbiota is established in germ-free mice via fecal transplantation to test the 
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contribution of a dysbiotic microbiome to a specific disease [38]. For example, Berer et al, 
transferred human-derived microbiota into transgenic mice expressing a myelin autoantigen-
specific T cell receptor, and showed that gut microbiota from multiple sclerosis-affected twins 
induced CNS-specific autoimmunity at a higher incidence, than microbiota from healthy co-
twins [39]. 
Most studies linking dysbiosis to a disease in the host is either at the bacterial genus or 
species level. Just as the metabolic function is strain-specific, pathogenicity is strain-specific as 
well. For e.g., the probiotic strain  E.coli strain Nissle 1917 lacks many of the virulence factors 
that many pathogenic E.coli possess and hence is used in the treatment of infectious diarrhea and 
IBD [40] elucidating how the same species can include probiotic or pathogen strains. 
 
1.2.2 Bacterial dysbiosis and gastrointestinal diseases 
Dysbiosis can facilitate invasion of the GI tract by enteropathogens, and lead to 
functional changes since gut bacteria participate and modulate many host metabolic processes 
(e.g., bile acid metabolism and fermentation and utilization of non-digestible carbohydrates and 
proteins), altered intestinal permeability, and motility leading to malabsorption and malnutrition 
in the host [8]. 
In veterinary medicine, alteration of gut microbiota has been reported in dogs, including 
acute and chronic gastrointestinal diseases [41]. Most commonly, the bacterial phyla Firmicutes 
(i.e., Lachnospiraceae, Ruminococcaceae, and Faecalibacterium) and Bacteroidetes are 
commonly decreased, with concurrent increases in Proteobacteria (i.e., Escherichia coli).  
 In dogs with acute diarrhea, culture independent studies have shown an increased 
 10 
 
 
abundance of E. coli, Enterococcus spp, C. perfringens, and Lactobacillus with an associated 
decrease in Faecalibacterium, Ruminococcaceae, and Blautia spp. [42-44].  
 Minamoto et al. reported a lower bacterial diversity and richness along with a bacterial 
dysbiosis marked by an increase in Gammaproteobacteria, and a concomitant decrease in 
Erysipelotrichia, Clostridia, and Bacteroidia in dogs with idiopathic IBD [45]. 
 
1.3 Bile acid metabolism and enterohepatic circulation 
Bile acids (BA) are an important class of compounds that are vital in lipid uptake and 
also as signaling molecules in different organs including the gut, liver, muscle and brown 
adipose tissue. They are initially synthesized from cholesterol in the liver and are further 
metabolized by the gut microbiota [46]. Bile acids are categorized into primary bile acids (PBA) 
and secondary bile acids (SBA).   
Primary bile acids are synthesized from cholesterol by a process that requires the 
concerted actions of at least 14 liver enzymes [47]. The rate-limiting enzyme cholesterol 7α-
hydroxylase (CYP7A1) initiates the classical pathway for bile acid synthesis, and CYP27A1 
initiates the alternative pathway [47]. The common primary bile acids produced are 
chenodeoxycholic acid (CDCA) and cholic acid (CA) in most mammalian species, except for in 
rodents who produce muricholic acid (MCA) [48]. In the hepatocytes, PBAs undergo 
conjugation (N-acyl amidation) with amino acids such as taurine or glycine to form bile salts. In 
most mammals, PBAs can conjugate to glycine in the absence of taurine, except for in dogs and 
cats [49]. Conjugation of bile acids increases their solubility and amphipathic properties that will 
assist in lipid absorption via micelle formation [50]. In dogs, taurine conjugation predominates, 
while in humans, glycine-conjugated BAs are predominant [51]. Conjugated bile acids are 
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concentrated and stored in the gall bladder. Meal induced secretion of cholecystokinin stimulates 
the release of stored bile salts from the gall bladder into the duodenum [50]. In the small 
intestinal lumen, they facilitate the absorption of triglycerides, cholesterol, and lipid soluble 
vitamins. Bile acids are efficiently reabsorbed (~95%) from the intestine, mainly by active 
transport mediated by the ileal bile acid transporter (IBAT; also known as ASBT or SLC10A2) 
but also through passive diffusion in the upper small intestine and colon [52]. This active 
reabsorption of bile acids from the ileum and circulation back to the liver via the hepatic portal 
vein is known as the enterohepatic circulation [50, 53]. The bile acids that are not reabsorbed 
escape into the large intestine where they become substrates microbial biotransformation and 
form SBAs [53]. SBAs form the major components of the total fecal bile acid pool. 
 
1.3.1 Role of bile acids  
The main role of bile acids includes emulsification of fats, release of fat-soluble vitamins, 
and regulation of cholesterol and glucose metabolism. Bile acids also act as signaling molecules 
and regulate the host metabolic machinery and immune systems. They bind to nuclear receptors 
like farnesoid X receptor (FXR), pregnane X receptor and vitamin D receptor and G protein-
coupled receptor TGR-5, which are expressed on various intestinal epithelial cells and within 
varied organs [54-56].  
Recently, bile acid receptor FXR-α, has gained interest for its role in glucose and energy 
homeostasis, along with regulation of inflammation and belongs to the nuclear receptor 
superfamily class II [57].  Ligands of this receptor subfamily are endogenous lipophilic 
compounds like cholesterol, lipids, bile acids and metabolites thereof [58, 59]. Conjugated and 
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unconjugated bile acids are the natural ligands for FXR-α  [60]. CDCA is the most potent ligand 
for FXR-α and cholic acid being the least potent [59].   
Recent studies highlight the role of the nuclear BA receptor FXR as a major regulator of 
hepatic BA synthesis. Activation of FXR in ileal enterocytes induces endocrine feedback 
expression of fibroblast growth factor (FGF19 – in humans and FGF15 – in mice), which 
attenuates the classical pathway of hepatic bile acid synthesis by downregulating the rate-
limiting enzyme, CYP7A1 [61]. 
Bile acid diarrhea in humans occurs when increased amounts of bile acids enter the colon 
and is primarily due to an interruption in enterohepatic circulation [62]. This leads to colonic 
fluid and electrolyte secretion [63] and motility changes (likely via the stimulation of myenteric 
ganglionic neurons) by TGR5) [33, 62].  In human patients with primary and secondary bile acid 
diarrhea, obeticholic acid (OCA), a potent FXR agonist that stimulates FGF-19 production and 
decreases hepatic bile acid synthesis, was administered at 25 mg orally, daily for two weeks; it 
decreased stool frequency, improved stool consistency, increased FGF-19 levels, and decreased 
serum C4 and serum bile acids [64]. 
Apart from being a key regulator of bile acid homeostasis, FXR-α also exhibits a 
tremendous number of direct and indirect target genes involved in lipid, glucose, and cholesterol 
homeostasis[65]. Glucose and insulin are regulators of FXR-α, and occurs, due to different 
promoter usage and alternative splicing, in 4 different isoforms (1 to 4), which differ in tissue 
distribution [61].  Studies in FXR deficient mice have shown developing signs of insulin 
resistance, further evidence suggests that FXR agonists may reduce blood glucose levels in 
murine models of obesity and diabetes [66, 67]. Downstream targets of FXR such as the 
hormones Fibroblast Growth Factor 15 and 19 (FGF 15 and FGF 19, respectively) have also 
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been implicated in diabetes mellitus. It has also been reported that FGF 15 and FGF 19 can 
suppress gluconeogenesis [68]. 
G-protein-coupled receptor (GPCR) for e.g., TGR5 is a bile acid specific membrane 
receptor, and is a member of the rhodopsin-like subfamily of GPCRs (Class A). The expression 
of TGR5 is universal but levels vary between tissues: high in gallbladder and low in brown 
adipose tissue (BAT), liver, intestine, monocytes/ macrophages and some areas of the central 
nervous system [69]. In dogs, TGR-5 was ubiquitously distributed in the gastrointestinal tract 
and was expressed predominantly in the membrane of epithelial cells and both in the membrane 
and cytoplasm of ganglia, histiocytes, and enteroendocrine cells [70].  
In humans, many bile acids can activate TGR5, but lithocholic acid (LCA) and 
taurolithocholic acid (TLCA) are the most potent endogenous ligands for TGR5 [71, 72]. TGR5 
modulates glucose and energy homeostasis as well as inflammatory responses. BA activation of 
TGR5 stimulated adenylate cyclase, rapid intracellular cAMP production, and protein kinase A 
activation. These regulatory functions of TGR5 play important roles in regulating energy 
metabolism in brown adipose tissue, relaxing and refilling gallbladder, secreting glucagon-like 
peptide 1 (GLP-1) in intestinal endocrine cells and controlling gastrointestinal motility to help 
maintain BA, lipid, and glucose homeostasis [73-75]. Furthermore, TGR5 are capable of 
reducing proinflammatory cytokines such as IL-1α, Il-1β, IL-6, and TNF-α [76].  
In addition to the role of bile acids in digestion and as signaling molecules, luminal bile 
acids also play a key role in regulating the host gut microbiota by preventing bacterial 
overgrowth and translocation in the small intestine thereby modulating the gut microbiota and 
maintaining membrane integrity [77]. Inagaki et al. were able to show that the antimicrobial 
effects of conjugated bile acids are due to their hydrophobicity and via their stimulation of 
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farnesoid X receptor (FXR) which results in the production of antimicrobial peptides [78]. 
Furthermore, activation of FXR by conjugated bile acids induced the expression of genes whose 
products prevent bacterial overgrowth and promote epithelial integrity [53, 77, 79].  
 
1.3.2 Role of microbiota in bile acid metabolism     
 Bacterial transformations of primary bile acids (PBA) involves the deconjugation of bile 
acids from their taurine or glycine conjugate via bile salt hydrolases (BSH), reversible 
epimerization between α and β orientations, and dehydroxylation [53]. BSH mediated 
deconjugation of bile salts is referred to as the “gateway” reaction as it is a pre-requisite for 
further modifications by the gut microbiota [80, 81].  
Many bacteria in the small and large intestine have BSH activity including Bacteroides, 
Clostridium, Enterococcus, Lactobacillus, Bifidobacterium, and Listeria [53, 80, 82]. Some 
archaea (e.g., Methanobrevibacter smithii and Methanosphera stadmanae) also have been 
reported to have BSH activity [82]. Free BAs solubilize intestinal lipids and their reabsorption is 
less efficient, which will result in increased fecal BA loss and an ameliorated metabolic 
adaptation of the host [83]. 
Apart from deconjugation, gut microbiota also carries out the reversible oxidation of the 
hydroxyl groups on the 3-, 7-, and 12- carbons of bile acids with the hydroxysteroid 
dehydrogenases (HSDH). Bile acid HSDHs have been found and characterized in numerous 
genera inhabiting the lumen of the colon, including Bacteroides, Clostridium, Escherichia, 
Eggerthella, Eubacterium, Peptostreptococcus, and Ruminococcus [53, 84, 85]. 
Once deconjugated, CDCA and CA undergo 7α-dehydroxylation to form the secondary 
bile acids (SBA), lithocholic (LCA) and deoxycholic acid (DCA).  7α-dehydroxylation is a 
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process by which bacterial hydratases remove the hydroxyl group from the seventh carbon of 
both CA and CDCA forming the secondary bile acids, deoxycholic acid (3α, 12α-dihydroxy-5β-
cholen-24-oic acid; DCA) and lithocholic acid (3α monohydroxy-5β-cholen-24-oic acid; LCA), 
respectively. Microbial enzymes are necessary for this conversion and explain why germ-free 
mice lack secondary bile acids when compared to conventional mice [54]. The secondary bile 
acids are partially absorbed in the intestine and following reconjugation in the liver, forms 
glycodeoxycholic acid, taurodeoxycholic acid, taurodeoxycholic acid, glycolithocholic acid, and 
taurolithocholic acid which are then excreted into the canaliculi. 
Only a few members of the genera Clostridium and Eubacterium with the bile acid-
inducible (bai) genes are able to carry out 7α-dehydroxylation [21]. Kakiyama et al. reported a 
significant correlation between fecal secondary bile acids and the members of the order 
Clostridiales [23]. The best studied and characterized 7α-dehydroxylating species is Clostridium 
scindens. Metagenomic studies have shown that human fecal samples have a high prevalence of 
C. scindens. Qin et al. identified C. scindens as a component of the “core microbiome”, a set of 
57 bacteria which were present in >90% of the cohort in their metagenomic study [86]. Despite 
its almost ubiquitous presence in human microbiota, it is populated at a very low relative 
abundance as quantified in this metagenomic surveys. C. scindens was found to be one of the 
lowest abundant member of the “core microbiome”, present at approximately two orders of 
magnitude lower than the most abundant bacteria in the human gut [86, 87]. A review of the 
literature, did not show any evidence of C. scindens being present in the canine fecal microbiota. 
As mentioned previously, in healthy individuals, 95% of all liver-secreted bile acids are 
reabsorbed in the ileum to be taken up by the liver through the enterohepatic circulation. Only a 
small part of the bile acid pool escapes the enterohepatic circulation and is excreted through 
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feces. Previous studies have shown that germ-free rats tend to accumulate more cholesterol than 
wild type rats that when fed a cholesterol-containing diet [88, 89]. Wostmann et al.showed that 
the bile of the adult germfree rat fed diets low in cholesterol (0.05% or less) contained 
approximately three times as much bile acid as found in the bile of conventional rats. Biliary bile 
acid composition of the germfree rat was similar to the bile acid composition found in its feces, 
except for a small predominance of tauro-β-muricholic acid in the feces resulting from 
preferential reabsorption of taurocholic acid in the ileum of the germfree rat [88].  
Studies have shown that germ-free animals retain higher levels of bile acids in 
enterohepatic circulation, increased levels of conjugated bile acids throughout the intestine with 
no deconjugation and decreased fecal excretion of bile acids [90, 91]. Swann et al. characterized 
the primary and secondary bile acids profiles in different tissues (liver, kidney, heart, and blood 
plasma) and showed that tissues in germ-free mice contained a significantly lower proportion of 
secondary and tertiary unconjugated and glycine-conjugated bile acids compared when compared 
to conventionally raised animals [92].  
Antibiotic-treated animals also showed an altered bile acid profile [93]. Miyata et al. 
showed that ampicillin treated mice had an increase in the bile acid transporter SLC10A2 mRNA 
levels and SLC10A2 protein, with a concurrent increase in hepatic bile acid levels and decreased 
fecal bile acids.   Discontinuation of ampicillin administration increased the levels of fecal bile 
acid excretion, and taurodeoxycholic acid and cholic acid in the intestinal lumen, and decreased 
the ileal SLC10A2 expression [93].  
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Figure 2. Bio-transformation of bile acids by gut microbiota. 
(adapted from Ridlon et al.[93]) 
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1.3.3 Bile acids in health and disease 
 The fine balance between gut microbiota and bile acid pool size/composition is necessary 
for maintaining host GI health. The interactions of BAs with the intestinal microbiota is vital to 
maintain a bile acid homeostasis and any perturbation to this balance can affect many host 
physiological functions [94, 95]. 
Irritable bowel syndrome (IBS) is a GI disorder that has a complex pathophysiology that 
presents with abdominal pain and is generally classified based on the symptoms as diarrhea 
predominant (IBS-D) or constipation predominant (IBS-C). In humans, approximately 30% of 
patients with IBS-D have BA malabsorption (BAM) [96, 97]. An increased proportion of 
primary BAs in the feces of IBS-D patients compared with healthy control subjects has been 
reported previously [98, 99] 
Bacterial dysbiosis induced alterations in bile acid profiles have been shown in human 
IBD patients (i.e., in ulcerative colitis and Crohn’s disease). Duboc et al. reported higher levels 
of conjugated bile acids and lower level of secondary bile acids in feces and an associated 
impairment in deconjugation and transformation activities of the microbiota in IBD patients 
[100].  
Clostridium difficile is an anaerobic spore former that is a pathogen responsible for 
causing C. difficile infection (CDI). Antibiotic use increases susceptibility to CDI, and is also 
characterized by an altered gut microbiota profile and a concomitant change in microbially 
mediated metabolites [101]. Host bile acids (especially cholic acid and taurocholic acid) in the 
small intestine is crucial for the germination of C. difficile spores into vegetative cells [102, 103]. 
Interestingly, the secondary bile acids - DCA, LCA UDCA and ω-muricholic acid (ω-MCA) 
inhibit the C. difficile spore germination and are major factors that influence resistance to this 
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infection [104]. Studies have shown that patients with CDI have high primary bile acid levels, 
with low levels of secondary bile acids [101, 105]. Mouse model studies have shown that the 
presence of C. scindens (a bile acid 7α-dehydroxylating bacterium) can directly inhibit C. 
difficile and thus provide resistance to CDI in the host [106, 107].  
Human studies have shown a reduction in bacterial groups such as Blautia, 
Ruminococcaceae and the Clostridium cluster XIVa group, which contain a high proportion of 
7α-dehydroxylating bacteria along with a decreased concentration of fecal secondary BAs in 
patients with advanced cirrhosis compared to controls [108, 109]. Based on these observations, 
Bajaj et al.introduced the “cirrhosis dysbiosis ratio” (CDR), which is defined as the ratio of 
Ruminococcaceae, Lachnospiraceae and Clostridiales cluster XIV, to Enterobacteriaceae and 
Bacteroidaceae. A lower index indicated dysbiosis [110]. A study in cirrhotic patients with synthetic 
deficits in production of bile acids found that increases in Enterobacteriaceae were positively 
associated with CDCA concentrations and lower concentrations of secondary bile acids in stool and 
this is speculated to be due to a concomitant reduction in typical resident groups of 7α-
dehydroxylating Clostridia [111]. 
The gut microbiota plays a role in the regulation of normal gastrointestinal function and have 
been attributed to affect the gut-brain axis signaling in autism spectrum disorder (ASD) [112]. A 
recent study in BTBR mice (a commonly used animal model for studying autism) by Golubeva et 
al.reported social and behavior deficits that were associated with marked GI distress and profound 
alterations in bacterial taxa. The decrease in Blautia was associated with deficient bile acid and 
tryptophan metabolism in the intestine, gastrointestinal dysfunction and impaired social interactions 
[113] in these mice.   
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In veterinary medicine, a recent 16S rRNA sequencing study showed that administration 
of metronidazole to healthy dogs altered the gut microbiota, with a decrease in commensal 
anaerobic bacterial taxa, and an increase in E. coli. Metronidazole administration also led to a 
decrease in secondary bile acids and an increase in oxidative stress in these animals [30]. 
An untargeted fecal metabolomics study by Honneffer et al.in dogs with idiopathic IBD 
showed several hundred significantly altered metabolites and analysis of these metabolites has 
indicated alterations in bile acid metabolism, tryptophan metabolism, and the pentose phosphate 
pathway [114].  
Preliminary work by Guard et al.showed that fecal bile acid profiles became less 
dominated by primary bile acids and shifted to a higher proportion of secondary bile acids in 
dogs with IBD undergoing treatment when compared to the bile acid profiles at the time of initial 
diagnosis in these dogs. However, despite improvement in clinical activity scores, bacterial 
dysbiosis was present even after 8 weeks of treatment [115].   
 There is increasing evidence that alteration of bile acid metabolism and dysbiosis is 
associated with gastrointestinal diseases, however, further studies are needed to understand the 
physiological effects as well as therapeutic targets necessary to correct bacterial dysbiosis and 
bile acid dysmetabolism. 
 
1.4 Hypothesis and research objectives  
1.4.1 Hypothesis 
The hypothesis of this study is that the presence of bile acid 7α- dehydroxylating 
bacterial species is necessary for normal bile acid metabolism by the canine intestinal microbiota  
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1.4.2 Research objectives  
The objectives of this research project are 1) to describe the fecal microbiota of dogs with 
exocrine pancreatic insufficiency and exploring bile acid 7α-dehydroxylating bacterial species 
with altered secondary bile acid concentrations in these dogs, 2) to isolate, identify and 
characterize bile acid 7α-dehydroxylating bacteria from canine feces and 3) to explore 
correlations between C. hiranonis and secondary bile acids using a species-specific PCR and 
secondary bile acids in fecal samples from healthy dogs and dogs with gastrointestinal disease. 
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CHAPTER II 
THE FECAL MICROBIOME OF DOGS WITH EXOCRINE PANCREATIC 
INSUFFICIENCY* 
 
 
2.1 Overview 
Exocrine pancreatic insufficiency (EPI) in dogs is a syndrome of inadequate synthesis 
and secretion of pancreatic enzymes. Small intestinal bacterial dysbiosis occurs in dogs with EPI 
and is reversed with pancreatic enzyme therapy. However, there are no studies evaluating the 
fecal microbiome of dogs with EPI. The objective of this study was to evaluate the fecal 
microbiome of dogs with EPI. Three day pooled fecal samples were collected from healthy dogs 
(n = 18), untreated (n = 7) dogs with EPI, and dogs with EPI treated with enzyme replacement 
therapy (n = 19). Extracted DNA from fecal samples was used for Illumina sequencing of the 
bacterial 16S rRNA gene and analyzed using Quantitative Insights into Microbial Ecology 
(QIIME) and PICRUSt was used to predict the functional gene content of the microbiome. 
Linear discriminant analysis effect size (LEfSe) revealed significant differences in bacterial 
groups and functional genes between the healthy dogs and dogs with EPI.  
 
 
 
 
*Reprinted with permission from Isaiah, A., Parambeth, J.C., Steiner, J.M., Lidbury, J.A., 
Suchodolski, J.S. 2017. The fecal microbiome of dogs with exocrine pancreatic insufficiency. 
Anaerobe 45, 50-58, Copyright (2017) Elsevier. 
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Based on analysis of similarity (ANOSIM) test, there was a significant difference in fecal 
microbial communities when healthy dogs were compared to treated and untreated dogs with EPI 
(unweighted UniFrac distance, ANOSIM P = 0.001, and 0.001 respectively). Alpha diversity was 
significantly decreased in untreated and treated EPI dogs when compared to the healthy dogs 
with respect to Chao1, Observed OTU, and Shannon diversity (P = 0.008, 0.003, and 0.002 
respectively). The families Bifidobacteriaceae (P = 0.005), Enterococcaceae (P = 0.018), and 
Lactobacillaceae (P = 0.001) were significantly increased in the untreated and treated dogs with 
EPI when compared to healthy dogs. In contrast, Lachnospiraceae (P < 0.001), and 
Ruminococcaceae (P < 0.01) were significantly decreased in dogs with EPI. Dogs with EPI 
(before treatment) had significant increases in functional genes associated with secretion system, 
fatty acid metabolism, and phosphotransferase system. In contrast, healthy dogs had a significant 
increase in genes related to phenylalanine, tyrosine and tryptophan biosynthesis, transcription 
machinery and sporulation. Furthermore, there was a significant difference in unconjugated bile 
acids 
 
2.2 Introduction 
 Exocrine pancreatic insufficiency (EPI) in dogs is characterized by the inadequate 
production of digestive enzymes by pancreatic acinar cells, which leads to maldigestion and 
malabsorption of nutrients. Clinical signs of dogs with EPI include weight loss despite 
polyphagia, steatorrhea, loose and voluminous, and /or malodorous stools [1-3]. A clinical 
suspicion is confirmed by the measurement of canine serum trypsin like immunoreactivity 
(cTLI), and a concentration of less than or equal to 2.5 µg/L is diagnostic for EPI [4]. EPI is a 
relatively common pancreatic disease in dogs with an estimated prevalence of approximately 7-
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9% of dogs tested using the canine trypsin-like immunoreactivity assay (cTLI) [5-7]. While this 
disease can affect any breed, certain breeds like German shepherd dogs (GSD) and Rough-coated 
collies are predisposed [5, 7].  
The main treatment for EPI in dogs is oral pancreatic enzyme replacement therapy, which 
is given with every meal. Affected dogs require lifelong therapy and about 60-65% of dogs have 
a good initial response to enzyme therapy alone. About 17-20% of dogs with EPI has a poor 
response to enzyme therapy alone [6, 8]. Therefore, additional measures such as, administration 
of antibiotics, antacids, and dietary interventions may be necessary based on the patient’s initial 
response to enzyme supplementation [9, 10]. Unfortunately, euthanasia due to a failure to 
respond to treatment is a common outcome [11]. 
Culture based methods have shown that small intestinal dysbiosis previously referred to 
as small intestinal bacterial overgrowth (SIBO) does occur in dogs with EPI. This has been 
attributed to the increased availability of undigested food material in the small intestinal lumen, 
lack of antibacterial factors in the pancreatic juice, changes in intestinal motility, and possibly 
altered gastrointestinal immune function [1, 2]. Previous studies show that small intestinal 
dysbiosis improves with pancreatic enzyme supplementation [1] and in the absence of an 
adequate response, tylosin administration reduces the small intestinal dysbiosis [2]. Small 
intestinal bacterial overgrowth has been reported previously been described to occur in GSDs 
[12]. The advent of culture independent molecular methods has deepened our understanding of 
the microbial alterations in various canine gastrointestinal diseases [13] and has identified 
numerous bacteria that were previously unculturable from the gastrointestinal contents and feces 
of subjects using conventional culture-based techniques.  Previous studies have shown 
differences in the fecal microbiome of dogs with acute diarrhea and inflammatory bowel disease 
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[14, 15]. To our knowledge, there are no studies using culture independent molecular methods of 
fecal samples, to study the dysbiosis that occurs in canine EPI.  
 A better understanding of the fecal microbiome and characterization of the dysbiosis that 
occurs in dogs with EPI will help in designing microbial/functional therapeutic strategies to 
better manage this challenging disease condition. Therefore, the aims of this study were to 
describe the fecal microbiome using and to predict the functional potential of the microbiota in 
dogs with EPI, enzyme supplemented and not enzyme supplemented with healthy control dogs.  
 
2.3 Materials and methods 
2.3.1 Study population 
Fecal samples were collected from client owned dogs with spontaneously occurring EPI 
and staff owned healthy dogs. This study was part of another clinical trial approved by the 
Clinical Research Review Committee at Texas A&M University and the study protocol has been 
reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) at Texas 
A&M University (AUP 2011-84) & IACUC 2014-0094 CA. 
Inclusion criteria for dogs with EPI were: a serum cTLI concentration ≤2.5 μg/L, which 
is considered to be diagnostic for EPI for this species, age ≥1-year, clinical signs of EPI 
(polyphagia, weight loss, steatorrhea, and/or loose, voluminous, and/or malodorous stools), and 
the absence of other concurrent diseases. The dogs with EPI were further divided into two 
groups; those that were treated with enzyme supplementation (EPI + E) and those that were 
untreated (EPI-E). 
The control group consisted of healthy pet dogs; all the dogs were older than 1 year, free 
from any clinically apparent disease and were not pregnant or lactating. None of the healthy dogs 
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had a history of gastrointestinal symptoms or antibiotic administration for at least a month prior 
sample collection, while five dogs in the EPI group (n = 5) were on antibiotics.  
 
2.3.2 Sample collection, DNA extraction, and 16S rRNA sequencing 
Three naturally voided fecal samples were collected on three consecutive days to account 
for variability. The samples were frozen immediately after collection and transported while they 
were still frozen. On arrival to the laboratory, samples were thawed at room temperature, pooled, 
and then an aliquot was used for DNA extraction using a MoBio Power soil DNA isolation kit 
(MoBio Laboratories, USA) following the manufacturer's instructions. Illumina sequencing of 
the bacterial 16S rRNA genes was performed using primers 515F (5′-
GTGCCAGCMGCCGCGGTAA-3′) to 806R (5′- GGACTACVSGGGTATCTAAT-3″) at the 
MR DNA laboratory, Shallowater, TX, USA (www.mrdnalab.com). 
 
2.3.3 Analysis of 16S rRNA dataset 
Sequences were processed and analyzed using Quantitative Insights Into Microbial 
Ecology (QIIME) v 1.8 [116, 117] as previously described [45]. The raw sequences were 
uploaded to NCBI Sequence Read Archive under the accession number SRP091334 (made 
available). The sequence data was demultiplexed, and then quality filtered using the default 
settings for QIIME. Chimeras were detected and filtered from the reads using USEARCH [118]  
against the 97% clustered representative sequences from the Greengenes v 13.8 database [119]. 
The remaining sequences were clustered into Operational Taxonomic Units (OTUs) by using an 
open reference approach in QIIME [117]. Taxonomy was assigned to representative sequences 
using the default QIIME parameters using uclust consensus taxonomy assigner and Greengenes 
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rRNA database version 13_8 (97% OTU representative sequences).    
  Prior to downstream analysis, sequences assigned as chloroplast, mitochondria, 
unassigned and low abundance OTUs, containing less than 0.01% of the total reads in the dataset 
were removed [120]. The samples from the EPI dataset, FMT dataset, and SCFA study were 
rarefied to an equal depth of 2,180 sequences per sample respectively to account for unequal 
sequencing depth. The rarefaction depth was chosen based on the lowest sequence depth of 
samples to have the optimum combination between the number of sequences and number of 
samples in the diseased group. Beta diversity was evaluated with the phylogeny based UniFrac 
distance [121] metric and visualized using Principal Coordinate Analysis (PCoA) plots with the 
workflow script beta_diversity_through_plots.py in QIIME. 
Linear discriminant analysis (LDA) effect size (LEfSe) was used to elucidate bacterial 
taxa that were associated with the sample categories. LEfSe analysis was carried out on the 
Galaxy server ((http://huttenhower.sph.harvard.edu/galaxy/) with the parameters set at α = 0.01, 
LDA score = 3.0. 
 
2.3.4 Statistical analysis 
The OTU tables generated from each study were also uploaded into Calypso, a web based 
application for visualization and statistical analysis of the data [122]. ANOSIM (Analysis of 
Similarity) test within PRIMER 6 software package (PRIMER-E Ltd., Luton, UK) was used to 
analyze significant differences in microbial communities between sample categories. All datasets 
were tested for normality using Shapiro-Wilk test (JMP Pro 11, SAS software Inc., NC, USA).  
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2.4 Results 
2.4.1 Sequence analysis         
 The sequence analysis yielded 2,263,390 quality sequences for all the analyzed samples 
(n = 44, mean ± SD = 51,074 ± 19,973) after removing chimeras, and singletons. The samples 
were rarefied to an equal sequencing depth of 2,180 reads per samples. 
 
2.4.2 Alpha diversity 
Alpha diversity, as described by species richness, Chao 1, and Shannon diversity index, 
was significantly decreased in dogs with EPI (Table 2). Species richness, as defined by the 
number of OTUs, was significantly decreased in dogs without enzyme supplementation (mean ± 
SD: 223.3 ± 68) and with enzyme supplementation (289.3 ± 111.3) when compared to healthy 
dogs (355.1 ± 53.81) (Table 1). 
 
2.4.3 Microbial communities 
EPI had a significant impact on the bacterial communities based on the PCoA plots, 
which showed healthy dogs clustering together when compared to dogs with EPI (Figure 3). 
There was a significant difference in microbial communities between healthy dogs and dogs with 
EPI based on an ANOSIM test. Healthy dogs clustered significantly different from EPI + E dogs 
(Pweighted, Punweighted = 0.001) and EPI-E dogs (Pweighted, Punweighted = 0.001). Also, when EPI + E 
dogs were compared to EPI-E dogs, there was a significant clustering of bacterial communities 
based on unweighted UniFrac distances (P = 0.026), which however was not significant when 
using the weighted UniFrac distance metric (P = 0.103). 
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There were no significant differences in the fecal microbiome of dogs due to age, gender, 
and breed based on ANOSIM (Table 2). As previously mentioned, five dogs had known 
antibiotic exposure prior to being enrolled in the study. ANOSIM based on unweighted UniFrac 
metric showed that prior antibiotic exposure could significantly influence the microbial 
communities (P = 0.037). However, this clustering was not significant when the analysis was 
based on weighted UniFrac distances (P = 0.129). A sub analysis, excluding the dogs that had 
prior antibiotic exposure, was conducted to avoid the potential confounding effects of this 
metavariable. With this sub-analysis, we were able to confirm our findings that the microbiome 
of dogs with EPI was different from healthy samples. 
 
2.4.4 Altered bacterial taxa in dogs with EPI 
Several bacterial taxa were found to be significantly different among the groups of dogs 
based on LEfSe (Figure 4) and Kruskal Wallis test (Table 3). At the family level, Clostridiaceae, 
Ruminococcaceae, Lachnospiraceae, Coriobacteriaceae were more abundant in healthy dogs 
when compared to the dogs with EPI. In contrast, the bacterial families Lactobacillaceae, 
Bifidobacteriaceae and Enterococcaceae are increased in dogs with EPI that were not treated 
(EPI-E) when compared to healthy samples. Dogs with EPI, that were on enzyme 
supplementation had an increased level of Streptococcaceae and Erysipleotrichaceae. 
Based on univariate statistics (Table 3), the genera, Faecalibacterium, Blautia, 
Coprococcus, [Ruminococcus], [Eubacterium], Bacteroides, Slackia, and Fusobacterium were 
significantly decreased in dogs with EPI. In contrast, Lactobacillus, Enterococcus, and 
Bifidobacterium were significantly increased in dogs with EPI when compared with healthy dogs 
(Table 3). 
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At the species level, Blautia producta, Clostridium hiranonis Faecalibacterium 
prausnitzii, Ruminoccocus gnavus, and Collinsella stercoris were significantly decreased in dogs 
with EPI (both EPI+E and EPI-E). Eubacterium biforme was significantly different between 
healthy and dogs with EPI that were not enzyme supplemented (Figure 5).  
 
2.4.5 Functional analysis          
 The average nearest sequenced taxon index (NSTI) for all samples for the metagenomic 
predictions was 0.07 ± 0.02 in this study. Low NSTI values indicate that PICRUSt could predict 
the functions of the microbiota in the canine feces. 
LEfSe identified 19 bacterial functions (Table 4) that were differentially abundant 
between the healthy and EPI - E samples. Some of the functions that were decreased in the EPI 
group of samples when compared to healthy samples were genes related to sporulation, 
transcription machinery, metabolism of energy, methane, arginine and proline, porphyrin and 
chlorophyll. Meanwhile, pathways related to secretion systems, ABC transporters, 
phosphotransferase (PTS), metabolism of xenobiotics, glycans, and purines were over-
represented in EPI-E. There were no differentially abundant genes detected in the EPI + E groups 
when compared to healthy and EPI - E dogs.  
 
2.5 Discussion 
There is a lack of knowledge regarding the changes in diversity and composition of the 
gut microbiome in dogs with EPI. We evaluated the changes in the fecal microbiome of dogs 
with EPI when compared to healthy dogs and identified differences in the fecal microbiota 
between healthy dogs and the dogs with EPI (enzyme supplemented and not enzyme 
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supplemented). Dogs with EPI had a distinct microbiota profile when compared to the healthy 
dogs. We also showed that in dogs with exocrine pancreatic insufficiency, bile acid metabolism 
was significantly altered. 
The healthy dogs clustered together and were spatially separated from the dogs with EPI. 
The differences in beta diversities were found to be due to significant decreases in prominent 
members of the intestinal microbiota (P < 0.05), such as the families Lachnospiraceae (i.e., 
genera Blautia, Coproccus and Ruminococcus), Ruminococcaceae (i.e. genus Faecalibacterium), 
along with a significant increase in Lactobacillus, Bifidobacterium and Enterococcus in dogs 
with EPI, when compared to healthy dogs.  
Healthy dogs had a higher species richness (observed OTUs and Chao1) and microbial 
diversity (Shannon index) than the diseased group. Our results, also show a non-significant trend 
in a gradation in bacterial richness and diversity (Healthy controls > EPI + E > EPI - E). There 
was also a significant difference in microbial community composition between the healthy and 
diseased cohorts of dogs (p<0.001). The healthy dogs clustered together and were spatially 
separated from the dogs with EPI. The differences in alpha and beta diversities were found to be 
due to significant decreases in prominent members of the intestinal microbiota (p<0.05), such as 
the families Lachnospiraceae (i.e., genera Blautia, Coproccus and Ruminococcus), 
Ruminococcaceae (i.e. genus Faecalibacterium), along with a significant increase in 
Lactobacillus, Bifidobacterium and Enterococcus in dogs with EPI, when compared to healthy 
dogs. Previous studies based on culture based methods have also shown an increased number of 
Lactobacillus and Streptococcus in the duodenum [123], the jejunum and colon of dogs with EPI 
[124].             
 In this study, we also used PICRUSt algorithm to predict the functional gene categories 
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based on 16S rRNA gene profiles and were able to identify several pathways to be differentially 
expressed between healthy dogs and dogs with EPI. The gut microbiome of dogs with EPI also 
had a decreased expression of genes that are responsible for the metabolism of energy, fatty 
acids, amino acids, vitamins, cofactors, glycans, and biosynthesis of secondary metabolites. Our 
results also show a significant increase in the expression of genes related to sporulation in 
healthy dogs and an increase of the class Clostridia within the healthy group.  The characteristic 
malabsorption and maldigestion in this disease condition leads to excess nutrients in the feces of 
dogs with EPI. Cessation of growth of Clostridia in the presence of excess carbon and nitrogen 
and exposure to oxygen [125, 126], may account for the decrease in obligate anaerobic Clostridia 
and genes related to sporulation in dogs with EPI.  The deficiency in pancreatic lipase, along 
with the decreased bacterial biotransformation of bile salts, could lead to fat malabsorption and 
consequently, they are excreted in the feces as fat droplets which explains the over representation 
of pathways related to the metabolism of fatty acids in the diseased group of dogs. 
In human medicine, cystic fibrosis is attributed to be one of the common causes of EPI in 
childhood leading to malabsorption and malnutrition [127]. Manor et al reported that the order 
Lactobacillales was found to be over represented and Clostridiales was depleted in the 
gastrointestinal tract of children with CF [128], and is concurrent with the findings of our study. 
Higher prevalence of Lactobacillus and Bifidobacterium along with the lower proportion of 
Clostridium leptum, C. coccoides have been reported in fecal samples in gastrointestinal 
disorders like inflammatory bowel disease [129] and short bowel syndrome [130]. Lactobacillus, 
Enterococcus, and Streptococcus are heterofermentative bacteria that can produce lactic acid. 
High numbers of lactic acid producing gram-positive bacteria in the gastrointestinal tract, has 
been thought to be linked to D-lactic acidosis which in turn has been reported to cause cognitive 
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and neurological impairment [131]. Elevated serum D-lactate has been reported in cats with 
gastrointestinal diseases and D-lactic acidosis has been reported as a secondary event in a cat 
with EPI [132]. Aggressive behavior and nervousness have been reported in dogs with EPI [133, 
134]. Clostridium cluster XIVa belonging to the family Lachnospiraceae, include bacterial 
members that can consume lactate and produce butyrate [135]. A decrease in this group, along 
with an increase in lactic acid producers could potentially leads to increased levels of lactate. 
Indeed, in the present study, dogs with exocrine pancreatic insufficiency had a 
significantly reduced number of gram-positive bacteria, especially bacteria belonging to the 
Firmicutes phylum (e.g. species belonging to the Clostridium clusters IV and XIVa), which was 
associated with a significant reduction in fecal secondary bile acid levels.  
It is important to point out some limitations of our study. Firstly, we evaluated only a 
small number of animals in the disease groups, which may have limited our ability to fully 
characterize the microbiome of dogs with EPI. Also, the samples from dogs with EPI that were 
enzyme supplemented, were single time point fecal samples, from dogs which had been treated 
with enzymes for various durations.  We could not discern the effect of pancreatic enzymes and 
antibiotics on the microbiome in the diseased group since some of the dogs with EPI, (EPI–E (n 
= 3) and EPI+E (n = 2)) had received tylosin that is known to influence the intestinal microbiome 
of dogs, which could have affected our results. However, the finding that untreated EPI (EPI-E) 
dogs, has a similar microbiome to treated dogs and is different from healthy dogs, suggests that 
the effect of antibiotics did not mask the changes due to EPI itself. This study did not follow the 
longitudinal progression of dysbiosis in the gut microbiome of dogs with EPI, before and after 
enzyme supplementation due to the nature of the disease, and ethical concerns about the health 
and discomfort in untreated client owned dogs. Consequently, the temporal changes in the gut 
 34 
 
 
microbiome in the diseased condition and in response to enzyme supplementation remain to be 
determined.  In addition, the question remains whether studying the fecal microbiome reflects the 
microbiome in the proximal sections of the gastrointestinal tract. Previous culture-based studies 
reported a small intestinal bacterial overgrowth in the jejunum, ileum and colonic contents in 
dogs with exocrine pancreatic sufficiency. Considering the difficulty in accessibility to samples 
from proximal regions of the small intestine, we only had access to fecal samples from dogs with 
EPI. Fecal microbial profiles, in humans, are said to mostly describe the luminal bacterial 
content [136]. Therefore, they may not truly represent the bacterial changes that occur in the 
epithelial and mucus associated bacterial communities in the gut. Hence, further studies with 
culture independent approaches that describe the bacterial and functional changes that occur in 
the small intestine of dogs with EPI using biopsy samples are warranted. However, this study 
clearly identified a dysbiosis in the fecal samples of dogs with EPI. Our study population was not 
homogenous, in terms of patient diet, or geographical location. While, these variables can alter 
the canine fecal microbiome, unless the disease is experimentally induced, it would be difficult 
to create a homogenous population to evaluate the effect of these factors. 
 In conclusion, this study describes the fecal bacterial community composition and 
predicted the metabolic potential of the microbiome based on 16S rRNA sequencing in dogs with 
EPI. Our findings show that the fecal microbiome and predicted function of dogs with exocrine 
pancreatic insufficiency is significantly different from healthy dogs and this warrants further 
studies.
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Table 1. Summary of alpha diversity measures. Reprinted with permission [137] 
  Healthy EPI before treatment 
EPI after 
treatment P-value 
Chao1 (mean ± SD)  832.71±200.18a 516.82±210.7b,c 651.32±269.05b,c 0.0081 
Observed OTU (mean ± SD)  355.06±53.81a 223.29±68.02b,c 289.32±111.34b,c 0.0033 
Shannon Index (mean ± SD)  6.37±0.54a 4.63±1.23b,c 5.28±1.46b,c 0.0016 
Means not sharing a common superscript differ (P<0.05, Dunn’s multiple comparisons test) 
 
 
 
 
 
 
Table 2. ANOSIM analyses on available metavariables in the study.  Reprinted with permission [137] 
Variable Weighted Unweighted 
  R value P value  R value P value  
Age group -0.0278 0.672 -0.0211 0.652 
Any prior antibiotic exposure 0.1526 0.145 0.2626 0.034 
Breed 0.0373 0.353 0.0093 0.456 
Disease group 0.4237 0.001 0.4148 0.001 
Gender 0.0204 0.294 0.034 0.184 
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Table 3. Relative percentages of the most abundant bacterial groups on the various phylogenetic levels (phylum, class, 
order, family, genus). Reprinted with permission [137] 
  Range (Minimum %-Maximum %)   Medians (%) * 
Bacterial Taxa Healthy EPI-E EPI+E   Healthy EPI-E EPI+E KW P value** 
Firmicutes 69-96.8 7.1-97.7 48.3-98.5   87.1 77.4 89.8 0.634 
   Clostridia 18.2-87.7 1.5-33.1 1.2-76   73.6 18.7 31.8 <0.001 
      Clostridiales 18.2-87.7 1.5-33.1 1.2-76   73.6 18.7 31.8 <0.001 
         Clostridiaceae 6.6-33.7 0.6-21.6 0.7-23.5   22 6.6 8.4 0.002 
            Other‡ 0-1 0-0.5 0-2.4   0.2 0 0.3 0.264 
            Unclassified‡‡ 3.1-15.3 0.3-8.5 0.3-19.2   6.3 1.2 2.6 0.013 
            Clostridium 0-21.6 0.1-15.1 0.1-12.2   0.5 3 1.2 0.457 
            SMB53 0.1-4.3 0-0.4 0-2.3   2.4 0.1 0.5 <0.001 
             Ruminococcaceae 0.4-12.9 0-3.8 0-7.3   1.9 0.1 0.6 0.005 
            Unclassified 0.3-9.5 0-2.8 0-5.4   1.6 0.1 0.5 0.008 
       Faecalibacterium 0-2.6 0-1 0-1.8   0.3 0 0 0.01 
         Lachnospiraceae 8.1-53.4 0.6-6 0.3-43.1   37.8 1 15.6 <0.001 
            Other 1.6-18.2 0-0.8 0-6   6.7 0.1 1.7 <0.001 
            Unclassified 1-7.7 0-1.7 0-6.6   5.1 0.2 1.4 <0.001 
            Blautia 3.7-30.6 0.2-3.1 0.1-23.5   15.1 0.5 6 <0.001 
            Coprococcus 0.1-1 0-1.6 0-3   0.5 0 0.2 0.036 
              [Ruminococcus]‡‡‡ 0.6-5.9 0-0.5 0-2.8   2.3 0.1 0.8 <0.001 
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Table 3. Continued.  
  Range (Minimum %-Maximum %)   Medians (%) *  
Bacterial Taxa Healthy EPI-E EPI+E   Healthy EPI-E EPI+E KW P value** 
         Peptostreptococcaceae 0.4-7 0.1-11.4 0.1-37.2   1.3 1.4 2.2 0.797 
            Unclassified 0.3-6.9 0.1-11.4 0.1-25.8   1.2 1.4 1.7 0.921 
         Veillonellaceae 0-13.1 0.1-13.6 0-21   0.6 0.3 0.6 0.797 
            Megamonas 0-12.5 0-13.3 0-8.8   0.4 0.1 0.2 0.812 
            Megasphaera 0-0.2 0-0.5 0-18   0.1 0.1 0.1 0.218 
         Unclassified 0.5-4.7 0-1.8 0-5.6   2 0.1 0.3 0.005 
         Other 0-1 0-0.5 0-2.4   0.2 0 0.3 0.273 
   Erysipelotrichi 0.2-5.7 0-1.8 0-26.5   1.3 0.2 0.5 0.093 
      Erysipelotrichales 0.2-5.7 0-1.8 0-26.5   1.3 0.2 0.5 0.099 
         Erysipelotrichaceae 0.2-5.7 0-1.8 0-26.5   1.3 0.2 0.5 0.103 
            Catenibacterium 0-2.0 0-1.1 0-2.7   0.3 0 0 0.011 
            [Eubacterium] 0-3.1 0-0.7 0-2.4   0.4 0 0.2 0.01 
            Unclassified 0-0.6 0-0.2 0-0.4   0.2 0 0 0.002 
   Bacilli 1-70.3 3.7-94.3 4.0-94.3   6.8 44.3 36.1 0.002 
      Lactobacillales 0.6-69.4 2.6-94 1-93.4   2.2 42.7 30.7 0.001 
         Enterococcaceae 0-1.5 0-54 0-4   0.1 0.4 0.4 0.018 
            Enterococcus 0-1.3 0-52.2 0-4   0.1 0.4 0.3 0.01 
         Streptococcaceae 0.3-44.5 0.5-34.1 0.5-83.7   0.8 0.8 19.3 0.015 
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Table 3. Continued  
  Range (Minimum %-Maximum %)  Medians (%)*  
Bacterial Taxa Healthy EPI-E EPI+E   Healthy EPI-E EPI+E KW P value** 
            Streptococcus 0.3-44.5 0.5-34.1 0.5-83.7   0.7 0.8 19.3 0.01 
         Lactobacillaceae 0.3-23.4 1.8-62.4 0.2-51.1   0.6 34.8 2 0.001 
            Lactobacillus 0.3-23.4 1.8-62.3 0.2-51.1   0.6 34.8 2 <0.001 
      Turicibacterales 0.1-39.3 0.3-8.5 0.1-15.8   0.8 0.5 2.9 0.482 
         Turicibacteraceae 0.1-39.3 0.3-8.5 0.1-15.8   0.8 0.5 2.9 0.464 
            Turicibacter 0.1-39.3 0.3-8.5 0.1-15.8   0.8 0.5 2.9 0.457 
                  
Proteobacteria 0.2-5.2 0.5-91.8 0.3-16.9   1.3 5.3 2.5 0.102 
   Betaproteobacteria 0-0.7 0-5.1 0-6   0.2 0.5 0.1 0.817 
      Burkholderiales 0-0.7 0-5.1 0-6   0.2 0.5 0.1 0.817 
         Alcaligenaceae 0-0.7 0-2.8 0-6   0.1 0.5 0.1 0.863 
            Sutterella 0-0.7 0-2.8 0-6   0.1 0.5 0.1 0.888 
   Gammaproteobacteria 0.1-4.0 0.1-8.6 0.1-16.7   0.8 0.8 1.7 0.231 
      Aeromondales 0-2.6 0-0.1 0-0.4   0 0 0 0.758 
      Enterobacteriales 0-4.0 0.1-8.4 0.1-16.6   0.2 0.8 1.7 0.065 
         Enterobacteriaceae 0-4.0 0.1-8.4 0.1-16.6   0.2 0.8 1.7 0.064 
             Unclassified 0-4.0 0.1-8.4 0.1-16.5   0.2 0.8 1.7 0.044 
                  
Bacteroidetes 0.2-18.8 0-10.6 0-6.5   5.2 0.1 1.1 0.029 
 39 
 
Table 3. Continued  
  Range (Minimum %-Maximum %)  Medians (%) *  
Bacterial Taxa Healthy EPI-E EPI+E   Healthy EPI-E EPI+E KW P value** 
   Bacteroidia 0.2-18.8 0-10.6 0-6.5   5.2 0.1 1.1 0.017 
      Bacteroidales 0.2-18.8 0-10.6 0-6.5   5.2 0.1 1.1 0.021 
         Bacteroidaceae 0.1-18.4 0-8.3 0-3.1   2.6 0 0.3 <0.001 
            Bacteroides 0.1-18.4 0-8.3 0-3.1   2.6 0 0.3 0.001 
         Prevotellaceae 0-7.7 0-10.4 0-3.9   0.2 0 0.2 0.261 
            Prevotella 0-7.7 0-10.4 0-3.9   0.2 0 0.2 0.245 
         [Paraprevotellaceae] 0-1.9 0-0.1 0-0.6   0.1 0 0 0.011 
            [Prevotella] 0-1.8 0-0.1 0-0.6   0.1 0 0 0.018 
                  
Actinobacteria 1.4-8.3 0.6-20.4 0-35.2   3.3 10.2 2.5 0.523 
   Actinobacteria (class) 0-3 0.3-19.5 0-31.6   0.2 6.4 0.7 0.009 
      Bifidobacteriales 0-2.8 0.3-19.5 0-31.6   0.1 6.3 0.7 0.004 
         Bifidobacteriaceae 0-2.8 0.3-19.5 0-31.6   0.1 6.3 0.7 0.005 
            Bifidobacterium 0-2.8 0.3-19.5 0-31.6   0.1 6.3 0.7 0.004 
   Coriobacteriia 1.1-7.8 0.-3.8 0-3.6   3.2 0.3 0.7 0.001 
      Coriobacteriales 1.1-7.8 0-3.8 0-3.6   3.2 0.3 0.7 0.001 
         Coriobacteriaceae 1.1-7.8 0-3.8 0-3.6   3.2 0.3 0.7 0.001 
            Collinsella 0-0 0-0.2 0-3.2   0 0 0 0.812 
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Table 3. Continued     
  Range (Minimum %-Maximum %)  Medians (%) *  
Bacterial Taxa Healthy EPI-E EPI+E   Healthy EPI-E EPI+E KW P value** 
            Slackia 0-0.7 0-0.2 0-0.2   0.2 0 0 0.008 
            Unclassified 1-7.1 0-3.8 0-2.9   2.9 0.3 0.4 <0.001 
                  
Fusobacteria 0.2-14.2 0.1-6.9 0-20.9   2.4 0.1 0.8 0.029 
   Fusobacteriia 0.2-14.2 0.1-6.9 0-20.9   2.4 0.1 0.8 0.015 
      Fusobacteriales 0.2-14.2 0.1-6.9 0-20.9   2.4 0.1 0.8 0.018 
         Fusobacteriaceae 0.2-14.2 0.1-6.9 0-20.9   2.4 0.1 0.8 0.017 
            Fusobacterium 0.0-1.4 0-0.5 0-1.3   0.2 0 0 0.004 
            Other 0.4-16 Apr-52 0.3-40   0.9 10.6 7.8 0.317 
**Kruskal Wallis (KW) P-values were adjusted for multiple comparisons based on the Benjamini and Hochberg False 
discovery rate  
* Medians not sharing a common superscript differ (P<0.05, Dunn’s multiple comparisons test) 
‡‡‡Square brackets=proposed taxonomic grouping according to Greengenes v.13.5 database used within QIIME 1.8 
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Table 4. Linear discriminant analysis of bacterial functional category and their associations with disease.  
Only an LDA score of >3.5 is shown.  Reprinted with permission [137] 
 
Diet LDA 
Unclassified | Cellular processes and signaling | Sporulation Healthy 3.543 
Metabolism | Amino acid metabolism | Arginine and proline metabolism Healthy 3.036 
Metabolism | Metabolism of cofactors and vitamins Healthy 3.496 
Metabolism | Metabolism of cofactors and vitamins | Porphyrin and chlorophyll metabolism Healthy 3.474 
Genetic information processing | Transcription | Transcription machinery Healthy 3.055 
Metabolism | Amino acid metabolism | Phenylalanine, tyrosine and tryptophan biosynthesis Healthy 3.208 
Metabolism | Energy metabolism | Methane metabolism Healthy 3.217 
Unclassified | Cellular processes and signaling Healthy 3.54 
Genetic information processing | Transcription Healthy 3.142 
Metabolism | Energy metabolism Healthy 3.586 
Environmental information processing | Membrane transport | Phosphotransferase system (PTS) EPI-E 3.359 
Metabolism | Xenobiotics biodegradation and metabolism EPI-E 3.555 
Unclassified | Poorly characterized | Function unknown EPI-E 3.076 
Metabolism | Glycan biosynthesis and metabolism EPI-E 3.044 
Metabolism | Metabolism of other amino acids EPI-E 3.081 
Metabolism | Nucleotide metabolism EPI-E 3.35 
Environmental information processing | Membrane transport | Secretion system EPI-E 3.141 
Environmental information processing | Membrane transport | ABC transporters EPI-E 3.446 
Metabolism | Nucleotide metabolism | Purine metabolism EPI-E 3.193 
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Figure 3. Principal coordinates analysis (PCoA) of microbial communities from the fecal samples of healthy dogs, dogs with 
EPI with (EPI+E) and without enzyme supplementation (EPI -E). The figure shows a 3D PCoA plot based on a) weighted 
UniFrac distances b) unweighted UniFrac distances of 16S rRNA genes. Analysis of similarity (ANOSIM) revealed clustering 
between the three groups (P = 0.01). Reprinted with permission [137] 
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Figure 4. Linear discriminant analysis of bacterial taxa and their associations with disease. Only an LDA score of >3.0 is 
shown. Reprinted with permission  [137]
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Figure 5. Bacterial species that were identified as significantly lowered in dogs with EPI 
by 16SrRNA sequencing. 
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CHAPTER III 
ISOLATION, IDENTIFICATION, AND CHARACTERIZATION OF CLOSTRIDIUM 
HIRANONIS, A BILE ACID 7α-DEHYDROXYLATING BACTERIA FROM CANINE FECES 
 
 
3.1 Overview 
Clostridium hiranonis is a Gram-positive obligate anaerobic bacterium known for its high 
level of bile acid 7α-hydroxylating activity.  The aim of this study was to isolate and characterize 
C. hiranonis from canine fecal samples. One fresh fecal sample was collected from a healthy 
mixed breed dog, plated on to Brucella blood agar, brain heart infusion agar, and reinforced 
clostridial agar plates, and incubated anaerobically for 24 hours. The resulting pure anaerobic 
colonies were identified using matrix-assisted desorption ionization–time of flight mass 
spectrometry (MALDI-TOF MS). The canine C. hiranonis isolates were evaluated for their 
morphological and phenotypic characteristics and antibiotic susceptibility. Furthermore, the 
isolates were also subjected to fatty acid methyl ester (FAME) analysis and whole genome 
sequencing.   
The canine isolates were similar morphologically and phenotypically to the reference 
strain C. hiranonis DSM 13275. The major cellular fatty acids included both saturated and 
unsaturated fatty acids, with oleic acid (18:1 ω9c) being the predominant fatty acid. FAME 
analysis based dendrogram also showed that the canine isolates were similar to DSM 13275 at 
the species level but not at the sub-species level. The genome of the canine isolates (CH1 and 
CH22) was approximately 2.94 Mb long and had a G+C content of 30.91%. Whole genome 
sequence analysis showed that both isolates possess genes for the enzymes bile acid 7-alpha 
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dehydratase (EC 4.2.1.106) and choloylglycine hydrolase (EC 3.5.1.24), which are essential for 
bile acid 7α-dehydroxylation and for deconjugation, respectively. In vitro tests for these 
functional abilities of the isolates are warranted. 
 
3.2 Introduction 
 Primary bile acids (PBA) are synthesized by the liver from cholesterol. Within the liver, 
bile acids (BAs) are either conjugated to taurine or glycine or sulfated and then excreted into the 
gallbladder where they form major components of bile. The gallbladder releases bile into the 
small intestine as a result of meal-induced hormonal stimulation of gallbladder and excretes bile 
into the small intestine wherein PBA solubilize and aid in the absorption of lipids and lipid-
soluble vitamins. Most of the conjugated bile acids are actively absorbed in the ileum and 
returned to the liver via the portal blood (enterohepatic circulation). The bile acid pool that 
escapes ileal absorption enters the large intestine and are acted on by the commensal microbiota.  
The conjugated bile salts are deconjugated into free bile acids by the enzyme encoded by 
the gene for the bacterial bile salt hydrolase enzyme (BSH). The bsh gene is present in many 
bacterial species residing in the gut (e.g., Bacteroides, Clostridium, Enterococcus, Lactobacillus, 
Bifidobacterium, and Listeria) [53, 80, 82]. The free bile acids then enter into a multi-step 
pathway that leads to the removal of the C7 α-hydroxyl group of PBAs through a series of 
oxidation reactions. This multi-enzyme pathway is referred to as bile acid 7α-dehydroxylation 
and yields secondary bile acids (SBAs).  
7α-dehydroxylation of the primary bile acids cholic acid and chenodeoxycholic acid is 
carried out by only a few bacterial species and leads to the formation of the SBAs, deoxycholic 
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acid (3α, 12α-dihydroxy-5β-cholen-24-oic acid; DCA) and lithocholic acid (3α-monohydroxy-
5β-cholen-24-oic acid; LCA) respectively. 
Only a few members of the genera Clostridium and Eubacterium with the bile acid-
inducible (bai) genes are able to carry out 7α-dehydroxylation [21]. Kakiyama et al.reported a 
significant correlation between fecal secondary bile acids and the members of the order 
Clostridiales [23]. Bacteria with bile acid 7α-dehydroxylating activity, have been isolated 
previously from human feces, or been inferred by sequence identity are within the Clostridium 
cluster XIVa [138].  These are obligately anaerobic, gram-positive bacilli. Clostridium scindens 
and C. hiranonis are described to have high bile acid 7α-dehydroxylating which is described to 
be at least 10 times higher than the those of C. leptum, C. hylemonae, C. bifermentans, and C. 
sordelii [139].  In dogs, 16S rRNA sequencing studies have reported C. hiranonis to be one of 
the abundant species of fecal microbiota [140, 141].  
The purpose of this study was to isolate and characterize C. hiranonis, a bile acid 7α-
dehydroxylating bacterium from canine feces. 
 
3.3 Materials and methods 
3.3.1 Bacterial strains and cultivation 
Clostridium hiranonis (DSM – 13275) that is known to have bile acid 7α-
dehydroxylating activity was used as a reference strain and was purchased from DSMZ (German 
Collection of Microorganisms and Cell Cultures, Braunschweig, Germany). The reference strain 
was cultured on Brucella blood agar plates (BBA; Anaerobe Systems, CA) for 48 hours at 37°C 
in an anaerobic chamber (855 AC, Plas-Labs, INC., Lansing, MI). 
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3.3.2 Isolation of Clostridium hiranonis from healthy canine feces 
 A fecal sample was collected immediately after defecation from a healthy dog and 
transferred to an anaerobic jar that was set up with an AnaeroPack (Thermo Fisher Scientific, 
MA, USA). The sample was then transferred to the anaerobic chamber as soon as possible. A 
fecal slurry 10% (w/v) was made using pre-reduced 0.1M phosphate buffered saline (PBS) with 
pH 7. Serial ten-fold dilutions were then prepared using pre-reduced peptone water. The 
inoculum was spread on BBA, brain heart infusion agar (BHI), and reinforced clostridial agar 
plates. Plates were incubated at 37°C under anaerobic conditions and examined daily. The 
colonies were harvested after 24-72 hours and subcultured by streaking for isolation of pure 
colonies.  
 
3.3.3 Bacterial species identification with MALDI-TOF-MS    
 The bacterial strains were isolated by cultivation on BBA in an anaerobic chamber at 
37°C after 1 day of incubation. For bacterial identification, matrix-assisted laser desorption–
ionization time-of-flight mass spectrometry (MALDI-TOF-MS) protein analysis was carried out. 
A single colony was selected from the culture plate using a sterile toothpick and directly 
deposited on to a spot on the MALDI-TOF target plate (Bruker Daltonics, Bremen, Germany). 
The colonies were spotted on to the target plate in duplicate fashion. Formic acid (FA) was 
added to one of the duplicate spots since a preparatory extraction with FA is reported to enhance 
Gram-positive bacterial identification [142].  The preparation was allowed to air dry and then 
overlaid with 2 µL of matrix solution (a saturated solution of α-cyano-4-hydroxycinnamic acid 
[(HCCA; Bruker Daltonics, GmbH, Bremen, Germany) in 50% acetonitrile and 2.5% 
trifluoroacetic acid (Fluka; Sigma-Aldrich, St. Louis, MO)]. The matrix solution was allowed to 
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air dry at room temperature for 5 minutes. The plate was placed in the MALDI-TOF 
spectrometer and spectra were collected.  BioTyper 3.0 software (Bruker Daltonics, Bremen, 
Germany) was used to compare the obtained spectra against the reference spectra of bacteria in 
the database and the resulting similarity value was expressed as a log score. From the resulting 
log scores, manufacturer-recommended score cut-offs were used to determine genus level (1.7 to 
1.9) or species level (≥2.0) of the organism. For this study, a Biotyper score cut-off of ≥2.0 was 
considered for reliable species identification a score ≥1.7 and <2 allowed identification at the 
genus level; and a score of <1.7 were considered unreliable [143-145].  
Isolates that were identified as C. hiranonis isolates were stored at -20°C in BHI broth 
containing 20% glycerol. 
 
3.3.4 Morphological and phenotypic characteristics 
Morphology characteristics of each isolate, i.e., Gram-staining and colony characteristics 
on solid media, were assessed. Gram staining was performed using a Gram staining kit (BD 
Biosciences, Franklin Lakes, NJ). Endospore staining was performed using Schaeffer-Fulton’s 
method using 5% (w/v) malachite green stain with 2% safranin as the counterstain [146]. Stained 
cells were examined using a light microscope at 40X magnification (Olympus BX43 and 
Olympus DP73 camera). 
 Colony morphology was observed after 24 hours of growth at 37°C on Brucella Blood 
agar plate under anaerobic conditions. Hemolysis was tested by streaking the colony on 
Columbia sheep blood agar. Motility was examined by stabbing active colonies of the isolates in 
pre-reduced sulfide indole motility medium.  
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Catalase and oxidase activities were estimated by standard procedures. Biochemical 
properties and substrate utilization were carried out using commercially available API ZYM and 
50 CH kits (BioMerieux, Marcy‐l'Etoile, France) according to the manufacturer’s instructions. 
After inoculation, the strips were incubated anaerobically for 4 and 24 hrs respectively.  
Acid tolerance of C. hiranonis isolates was determined in accordance with a method 
previously described [147]. In brief, 10 μL of overnight bacterial culture in BHI broth was 
inoculated respectively into 1 mL of pH 2.0, 3.0, and 6.4 (control) BHI broth. For testing the bile 
acid tolerance of the C. hiranonis isolates, 1% overnight cultures in BHI broth were inoculated 
respectively into BHI broth with added 0.3% (w/v) oxgall (test) and without oxgall (control) and 
incubated in 37oC in an anaerobic chamber. 
 Antibiotic susceptibility to determine the minimum inhibitory concentration (MIC) of C. 
hiranonis isolates were tested using a gradient endpoint method (E-test) as previously described 
[148]. The antibiotics tested included amoxicillin with clavulanate, penicillin, clindamycin, 
metronidazole, and chloramphenicol. Minimal inhibitory concentrations (MICs) were determined 
for each antibiotic after 48 hours of incubation.  
 
3.3.5 Phylogenetic analysis and classifications 
DNA was extracted from the C. hiranonis isolates. PCR amplification of the 16S rRNA 
gene was performed using the primers- 515F (5´-GTGCCAGCAGCCGCGGTAA-3´, 515-533) 
and 13R (5´-AGGCCCGGGAACGTATTCAC-3´, 1390-1371) [149]. The amplicons were 
purified and sequenced at Eton Biosciences (San Diego, CA). The 16S rRNA gene sequence was 
compared to the GenBank database using the BLAST program (NCBI) for species identification. 
The isolate is considered as a new species if the percentage of similarity is <98.7%.   
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 The phylogenetic tree was constructed using a neighbor-joining method and the 
maximum composite likelihood substitution model with 1000 bootstraps on MEGA6 (Molecular 
Evolutionary Genetics Analysis) software [150]. 
 
3.3.6 Fatty acid methyl ester (FAME) analysis by gas chromatography/mass spectrometry 
(GC/MS) 
 Cellular fatty acids in prokaryotes are highly conserved due to their role in cell structure 
and function. They are major components of the lipid bilayer of bacterial membranes and 
lipopolysaccharides. FAME is a common method used for taxonomic and identification purposes 
in which whole cell fatty acids are converted to their methyl esters and then analyzed by gas 
chromatography [151-153]. The canine C. hiranonis isolates were sent to Microbial ID (Midi 
Inc., Newark, DE) and were analyzed using the Anaer1 method of the Sherlock® Microbial 
Identification System.  
A dendrogram, based on the fatty acid profiles of the isolates, was generated by 
clustering the Euclidean distances of the fatty acids to compare the degree of relatedness between 
the canine isolates and the reference strain C. hiranonis DSM 13275.  Isolates linked at a 
Euclidean distance (ED) of 10 units are considered to belong to the same bacterial species; those 
linked at an ED of 6 units are considered to belong to the same subspecies; and those that are 
linked at an ED between 2 and 4 generally are considered to be the same strain [154-156] 
 
3.3.7 Genome sequencing         
 Genomic DNA of C. hiranonis isolates was sequenced using the HiSeq Technology 
(Illumina, San Diego, CA) at MR-DNA (www.mrdnalab.com, Shallowater, TX). The libraries 
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were prepared using the Nextera DNA Sample preparation kit (Illumina Inc, San Diego, CA) 
following the manufacturer's user guide. The initial concentration of DNA was evaluated using 
the Qubit® dsDNA HS Assay Kit (Life Technologies, Carlsbad, CA), and 50 ng DNA was used 
to prepare the libraries and underwent simultaneous fragmentation and addition of adapter 
sequences. These adapters were utilized during a limited-cycle (5 cycles) PCR in which unique 
indices were added to the samples. Following the library preparation, the final concentration of 
the library was measured using the Qubit® dsDNA HS Assay Kit (Life Technologies, Carlsbad, 
CA), and the average library size was determined using the Agilent 2100 Bioanalyzer (Agilent 
Technologies, Santa Clara, CA).  The libraries were pooled and diluted (to 10.0 pM) and 
sequenced paired end for 500 cycles with an average coverage of 50X using the Illumina HiSeq 
system. 
 
3.3.8 Genome assembly and annotation 
 C. hiranonis genome was assembled and annotated using the bioinformatics database and 
analysis resource Pathosystems Resource Integration Center (PATRIC) gene annotation service 
(https://www.patricbrc.org/app/Annotation) [157, 158]. Paired-end reads were assembled into 
contigs using the ‘auto’ assembly strategy on PATRIC, which runs BayesHammer [159]  on 
short reads, followed by two assembly strategies that included Velvet [160] and Spades [161]. 
The resulting contigs were uploaded to PATRIC, which uses the RAST tool kit (RASTtk) [162]  
to annotate the genomic features.  
 
3.3.9 Comparative genomics         
 The genome viewer within PATRIC was used to visualize all the contigs within the 
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assembly. A feature table for the C. hiranonis isolates was created using PATRIC. Specialty 
genes tool within PATRIC was utilized to show all the features in the genome that have 
homology to genes that have been previously described to have specific properties.   
Proteome comparison within PATRIC was used to compare the bile acid 7-alpha 
dehydratase (EC 4.2.1.106) (BA7 alpha dehydratase) (bile acid-inducible operon protein E) 
within the reference genome (C. hiranonis DSM 13275) and the genomes of the canine isolates 
(CH1 and CH22). A phylogenetic tree based on conserved protein sequences was studied using 
the FastTree method within PATRIC. 
 
3.4 Results  
3.4.1 Isolation and identification of bacteria from canine feces 
 After inoculation of fecal samples on different media, the agar plates were inspected for 
growth after 24 and 48 hrs. Bacterial colonies were isolated for identification and biochemical 
testing by subculture to BBA plates and confirmed as anaerobes by growth only in the absence of 
oxygen. 
 
3.4.2 Identification of isolates using MALDI-TOF MS     
Anaerobes were then subjected to identification by MALDI-TOF MS. This method has 
been deemed as suitable for the identification of anaerobic bacteria. However, the correct 
identification of the isolates was dependent on the presence of the mass spectra of the reference 
species being in the Biotyper 3.0 database. The isolates that were identified using MALDI-TOF 
included Clostridium hiranonis, Ruminococcus gnavus, Bacteroides copracola, Blautia sp, 
Megamonas sp., Lactobacilli, and Prevotella copri. The results obtained by MALDI-TOF MS is 
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shown in Table 5 and enabled species level identification of 13 isolates (log score of >2). The 
remaining isolates had a probable identification at the genus level. Five isolates could not be 
identified with MALDI-TOF MS. Two isolates, 1 and 22, were identified as C. hiranonis, which 
were subsequently named as CH1 and CH22 respectively.  
 
3.4.3 Morphological and phenotypic identification of isolates 
The isolates were assessed for their gram staining properties and morphological 
appearance. Colonies were opaque and were 0.7-1 mm in size and had undulate margins after 24 
hours incubation on BBA plates. The colonies became larger upon extended incubation for 48 
hours. Bacterial cells were Gram- positive bacilli (Figure 6).  
CH1 and CH22 were strict anaerobes and non-motile. No free spores or endospores could 
be visualized after the Schaeffer-Fulton method. The isolates were strict anaerobes and exhibited 
optimum growth at 37°C with an incubation period of 48 hours. Both isolates grew in the tested 
pH concentrations of 2, 3, 7, 8.5 and also in 0.3% oxgall supplemented peptone yeast glucose 
(PYG) broth. 
Carbohydrate utilization and enzymatic activities of CH1, CH22, and DSM 13257 are 
shown in Table 6. All three isolates fermented glucose and fructose. CH22 and DSM 13257 but 
not CH1 fermented mannose. The isolates were negative for production of catalase, indole, or 
urease. The enzyme activities of the isolates were tested and all three isolates were positive for 
the presence of alkaline phosphatase, esterase lipase, naphthol-ASBI-phosphohydrolase, α-
mannosidase, and N-acetyl-β-D-glucosamidase. 
The canine C. hiranonis isolates were susceptible to penicillin, amoxicillin and 
clavulanate, metronidazole, chloramphenicol, and clindamycin as shown in Table 7.   
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3.4.4 Fatty acid characterization 
The predominant cellular fatty acid component of C. hiranonis was 18:1 ω9c (oleic acid) 
which contributed to 38, 36, 34% of the total cellular fatty acids in CH1, CH22, and DSM 13257 
(Table 8). Other important cellular fatty acids were 16:0 DMA (1,1-dimethoxyhexadecane), 18:1 
ω9c DMA ((9Z)-1,1-dimethoxy-9-octadecene), 16:1 ω7c ((9Z)-9-hexadecenoic acid; palmitoleic 
acid), 16:0 (hexadecanoic acid; palmitic acid), 11:0 iso (9-methyldecanoic acid, 9-methylcapric 
acid), and13:0 iso (11-methyldodecanoic acid; isotridecanoic acid). Since C. hiranonis was not 
in the FAME reference library of different isolates at MIDI, the closest match was based on the 
reference strain that was sent along with the isolates. The dendrogram cluster analysis based on 
fatty acid methyl ester profiles based on Euclidean distances showed that the canine C. hiranonis 
isolates have similar fatty acid profiles and cluster separately from the C. hiranonis DSM 13275 
(Figure 7). The Euclidean distances calculated between the canine C. hiranonis isolates was less 
than 4, which implies that they can be the same strain. However, the distance found between the 
canine isolates and C. hiranonis DSM 13275 is less than 10, which implies that they are the same 
bacterial species but possibly a different sub-species and strain in relation to C. hiranonis DSM 
13275. 
 
3.4.5 Whole genome sequencing of canine C. hiranonis isolates 
3.4.5.1 Genome properties        
 Comparing the relatedness of whole genomes should result in a better resolution of the 
phylogenetic relationship than single and multiple gene identities [163]. Hence, determining 
whole genomic DNA relatedness by the traditional DNA–DNA hybridization is considered the 
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gold-standard for species delimitation of prokaryotes. Nowadays, Whole Genome Sequencing 
(WGS) offer different and global approaches to support species delineation. 
Since little is known about C. hiranonis, we sequenced and assembled draft genomes of 
the canine isolates and compared it to the reference strain DSM 13257, which is a human isolate. 
The assembly of the canine C. hiranonis isolates resulted in 65 and 60 contigs for CH1 and 
CH22, respectively. Clostridium hiranonis DSM 13257, a public genome within PATRIC was 
used as a reference genome. Clostridium hiranonis contains a single, circular chromosome and 
the genome sizes were approximately 2.94 Mb for the canine isolates CH1 and CH22, 
respectively. The CH1 and CH22 isolates had a low G+C content of 30.9 %, which is similar to 
the G+C content of 31 % for the reference genome DSM 13257. No plasmids were detected in 
the canine isolates or the reference genome. The basic statistics and general features of the 
genomes of the two canine isolates are shown in Table 9. 
3.4.5.2 Comparative genomics  
The chromosome of CH1 isolate contained 2,767 protein coding DNA sequences (CDS) 
of which 1,219 were annotated as hypothetical proteins and 1,548 proteins had functional 
assignments as shown in Table 9. CH22 isolate contained 2,761 predicted protein CDS and 1,216 
of those were annotated as hypothetical proteins and 1,545 proteins with functional assignments. 
The circular genome maps of the two canine isolates of C. hiranonis are shown in Figure 8. 
3.4.5.3 Metabolic pathways 
 Analysis of the CDS predicted from the CH1 and CH22 genomes also showed the 
presence of the set of enzymes necessary for the glycolytic pathway. Due to the anaerobic 
growth requirements of the organism, enzymes for the oxidative phase of the pentose phosphate 
pathway could not be detected. Enzymes necessary for the metabolism of carbohydrates 
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(sucrose, fructose, and mannose, starch), lipids, nucleotides (purines and pyrimidines) were 
detected in both the canine C. hiranonis isolates. 
  Genes encoding the enzymes necessary for most of the enzymes for amino acid 
biosynthesis were detected. Enzymes for the metabolism of beta-alanine, taurine and 
hypotaurine, selenoamino acids, cyanoamino acids, D-glutamine, D-glutamate, D-alanine, and 
glutathione were also present.    
Another gene encoding a niche-specific functionality is the predicted choloylglycine 
hydrolase (EC 3.5.1.24) and these enzymes belong to the family of bile salt hydrolases (BSHs), 
also known as conjugated bile acid hydrolases (CBAHs) and are widespread among intestinal 
microbes. The gene encoding bile acid 7α-dehydratase (EC 4.2.1.106) was also detected in the 
genomes of the two canine isolates (Figure 9), however, it was not detected in the reference 
genome of C. hiranonis DSM 13257.  
Specialty genes detected included the genes for antibiotic resistance (tetracycline), 
virulence factor (translation elongation factor Tu), and mobile genetic elements. Both the canine 
isolates contained gene cluster encoding a CRISPR-Cas system of genes consisting of CRISPR 
associated (Cas) proteins that were identified as Cas 1, Cas2, Csd2/Csh2 family and RecB family 
exonuclease Cas4.  
A phylogenetic tree based on conserved proteins predicted based on WGS data was 
constructed (Figure 10). The canine isolates clustered close to each other and were similar to the 
reference sequence. 
 
3.5 Discussion         
 Clostridium hiranonis is a gram-positive rod shaped bacterium that is one of the 
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predominant members of the canine fecal microbiota [164]. The first isolation of what would be 
later named as C. hiranonis was from normal healthy fecal samples from an adult human by 
Hirano et al.in 1981 [165]. The strain was designated as HD-17 and was shown to deconjugate 
and 7α-dehydroxylate bile acids. In 1994, another bile acid 7α-dehydroxylating strain was 
isolated by Takamine et al.and was designated as TO-931 [166]. These strains were described as 
similar to C. sordelli. Doerner et al.were able to demonstrate the presence of bai-like genes in 
these strains [167]. In 2001, these strains were named as C. hiranonis and placed in Clostridium 
cluster XI, which contains C. bifermentans and C. sordelii.[168]. The type strain of this species 
is TO-931. 
This study describes the isolation of C. hiranonis, a gram-positive bacterium with known 
bile acid 7α-dehydroxylation from canine feces. Based on biochemical tests, fatty acid methyl 
ester analysis, and whole genome sequencing these isolates are similar to each other but different 
at a strain level from the type species C. hiranonis DSM 13257. The canine isolates were acid 
tolerant and grew in the presence of bile salts. The isolates were susceptible to amoxicillin with 
clavulanate, penicillin, clindamycin, metronidazole, and chloramphenicol 
 The major cellular fatty acid component of the canine C. hiranonis isolates was oleic 
acid. Other bacteria with oleic acid as the major cellular fatty acid include Acinetobacter 
baumannii [169], Lactobacillus buchneri, Bifidobacterium longum [170], and  Veillonella 
species [171].  A previous study found oleic acid (18:1 ω9c), as the major cellular fatty acid of 
Bacillus cereus strains that were grown on sporulation medium containing sheep blood and 
associated the possibility of blood containing media to be the source oleic acid [172]. The C. 
hiranonis isolates in this study were also grown on blood containing media, which may explain 
why oleic acid is the major cellular fatty acid of C. hiranonis.  
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One of the challenges for bacteria inhabiting the GI tract is to detoxify the by the host 
secreted bile acids. The bile acid composition has been shown to regulate the gastrointestinal 
microbiota and vice versa. In both canine isolates of C. hiranonis, the bile acid converting 
enzyme choloylglycine hydrolase (EC 3.5.1.24) was identified.  This enzyme belongs to the 
family of bile salt hydrolases (BSH) and is present in many gram-positive bacteria. BSH 
catalyzes the hydrolysis of the amide linkage in conjugated bile acids and this reaction is 
described as the “gateway reaction” for bacterial biotransformation of bile acids. 
In addition to BSH, the canine isolates also possess the gene encoding bile acid 7α-
dehydratase (EC 4.2.1.106), which is a part of the multi-step 7α/β dehydroxylation that is 
responsible for the conversion of PBAs to SBAs.  The bile acid 7α-dehydroxylation activity of 
C. hiranonis has been previously described [138]. The presence of this pathway allows bacteria 
to occupy a special niche to utilize PBAs as an electron acceptor, for energy and growth. 
In summary, this study was able to successfully isolate and identify C. hiranonis from 
canine feces. The genes for the enzymes choloylglycine hydrolase and bile acid 7α-dehydratase 
were identified in the whole genome sequence of both the canine C. hiranonis isolates. In vitro 
and in vivo studies are needed to further verify the 7α-dehydroxylating ability of the canine C. 
hiranonis isolates. 
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Table 5: Identification of bacterial isolates from 
canine feces using MALDI-TOF 
Isolate no. 
Best matched organism  
from the database  Score  
1 Clostridium hiranonis 2.26 
2 Ruminococcus gnavus 2.43 
3 No organism ID possible  1.42 
4 Ruminococcus gnavus 2.03 
5 Ruminococcus gnavus 2.05 
6 Bacteroides copracola 2.49 
7 Bacteroides copracola 2.39 
8 No organism ID possible 1.32 
9 Prevotella copri 2.21 
10 Ruminococcus gnavus 2.09 
11 Ruminococcus gnavus 2.01 
12 Streptococcus gallolyticus 2.03 
13 No organism ID possible 1.07 
14 No organism ID possible 1.25 
15 Streptococcus gallolyticus 1.92 
16 Streptococcus gallolyticus 2.1 
17 No organism ID possible 1.47 
18 No organism ID possible 1.25 
19 No organism ID possible 1.42 
20 No organism ID possible 1.35 
21 Bacteroides copracola 2.16 
22 Clostridium hiranonis 2.47 
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Table 6: Biochemical tests       
Test 
DSM 
13275 CH1 CH22 
 
Gram stain  Positive  Positive  Positive  
Production of:    
Indole (-) (-) (-) 
Urease (-) (-) (-) 
Catalase (-) (-) (-) 
apiZYM    
Alkaline phosphatase (+) (+) (+) 
Esterase (C 4) (-) (-) (-) 
Esterase lipase (C8) (+) (+) (+) 
Lipase (C14) (-) (-) (-) 
Leucine arylamidase (-) (-) (-) 
Valine arylamidase (-) (-) (-) 
Cystine arylamidase (-) (-) (-) 
Trypsin (-) (-) (-) 
α-chymotrypsin (-) (-) (-) 
Acid Phosphatase (-) (-) (-) 
Naphthol-ASBI-phosphohydrolase (+) (+) (+) 
α-galactosidase (-) (-) (-) 
β-galactosidase (-) (-) (-) 
β-glucuronidase (-) (-) (-) 
α-Glucosidase (-) (-) (-) 
β-Glucosidase (-) (-) (-) 
N-acetyl-β-D-glucosamidase (+) (+) (+) 
α-mannosidase (+) (+) (+) 
α-fucosidase (-) (-) (-) 
Fermentation of:     
Glycerol No No No 
Erythritol No No No 
D-Arabinose No No No 
L-Arabinose No No No 
Ribose No No No 
D-Xylose No No No 
L-Xylose No No No 
Adonitol No No No 
Methyl-βD-xylopyranoside No No No 
D-Galactose No No No 
D-Glucose Yes Yes Yes 
D-Fructose Yes Yes Yes 
D-Mannose Yes Yes Yes 
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Table 6: Continued       
Test 
DSM 
13275 CH1 CH22 
L-Sorbose No No No 
L-Rhamnose No No No 
Dulcitol No No No 
Inositol No No No 
D-Mannitol No No No 
D-Sorbitol No No No 
Methyl-αD-mannopyranoside No No No 
Methyl-αD-glucopyranoside No No No 
N-acetyl glucosamine No No No 
Amygdaline No No No 
Arbutine No No No 
Esculine No No No 
Salicine No No No 
Cellobiose No No No 
Maltose No No No 
Lactose No No No 
D-Melibiose No No No 
D-Saccharose No No No 
D-Trehalose No No No 
Inulin No No No 
D-Melezitose No No No 
D-Raffinose No No No 
Starch No No No 
Glycogen No No No 
Xylitol No No No 
Gentiobiose No No No 
D-Turanose No No No 
D-Lyxose No No No 
D-Tagatose No No No 
D-Fucose No No No 
L-Fucose No No No 
D-Arabitol No No No 
L-Arabitol No No No 
Gluconate No No No 
Potassium 2-Keto-gluconate No No No 
Potassium 5-Keto-gluconate No No No 
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Table 7: Antimicrobial susceptibility of C. hiranonis isolates. MIC values (in 
μg/ml) of 5 antimicrobial agents when tested by E-test 
Isolate CH1 CH22 
DSM 
13257 
Penicillin 0.064 (S) 0.38 (S) 0.25 (S) 
Amoxicillin with clavulanate 0.094 (S) 0.38 (S) 0.25 (S) 
Metronidazole < 0.016 (S) 0.125 (S) 0.25 (S) 
Chloramphenicol 1 (S) 3 (S) 4 (S) 
Clindamycin  0.25 (S) 0.125 (S) 0.75 (S) 
(S) – Susceptible by CLSI standards 
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Table 8: Cellular fatty acid composition of the C. hiranonis isolates (in %) 
Cellular fatty acid  CH1 CH22 DSM 13275 
11:0 iso  3.95 5.16 4.29 
11:0 anteiso TR ND TR 
12:0 iso  TR TR TR 
12:0  ND ND TR 
13:0 iso  3.71 4.79 4.73 
13:0 anteiso  ND 2 1.91 
14:1 ω5c TR ND TR 
14:0 2.4 2.45 1.52 
14:0 DMA TR TR 1.59 
15:0 iso TR 1.26 TR 
15:0 anteiso ND ND TR 
16:0 aldehyde 1.91 2.62 1.57 
15:0 iso DMA TR TR 1.12 
16:1 ω7c 4.89 5.21 3.82 
16:0 3.98 5.25 1.23 
16:1 ω7c DMA TR TR 1.07 
16:0 DMA 6.42 7.25 5.26 
17:0 iso 1.86 1.9 0.57 
18:0 aldehyde ND ND TR 
17:0 anteiso DMA ND ND 1.02 
18:1 at 17.254 DMA ND ND 0.59 
18:2 ω6,9c 3.15 3.55 1.35 
18:1 ω9c 38.76 36.96 34.01 
18:0 1.28 1.51 0.52 
18:1 ω9c DMA 5.71 4.24 12 
18:1 ω7c DMA 2.04 1.69 3.02 
18:0 DMA 2.18 2.66 2.05 
19:0 anteiso ND ND TR 
ND: Not detected 
TR: Traces (<1%) 
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Table 9: Nucleotide content and gene count levels of C. hiranonis genomes 
Feature  CH1 CH22 
DSM 
13275 
Contigs 65 60 18 
Genome Length 29,40,846 29,38,933 24,70,519 
GC Content 30.91 30.91 31 
PATRIC CDS 2,767 2,761 2,175 
repeat_region 129 115 2275 
tRNA 67 61 30 
rRNA 13 15 3 
Hypothetical proteins 1,219 1,216 848 
Proteins with functional assignments 1,548 1,545 1,327 
Proteins with EC number assignments 586 584 527 
Proteins with GO assignments 470 468 550 
Proteins with Pathway assignments 403 403 379 
Proteins with PATRIC genus-specific family (PLfam) 
assignments 0 0 0 
Proteins with PATRIC cross-genus family (PGfam) 
assignments 1,475 1,476 1,346 
Proteins with FIGUREfam assignments 1,861 1,860 1,908 
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Figure 6. Cell morphology and Gram staining of canine C. hiranonis isolates  
A) CH1 B) CH22 by light microscopy (bar 20μm). 
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Figure 7. Dendrogram cluster analysis based on fatty acid methyl ester profiles of C. hiranonis 
isolates. Samples linking below 12 Euclidean distance (ED) belong to the same species. Samples 
linking below 4 ED are the same strain.   
Euclidean distance 
CH22 
CH1 
DSM 13275 
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Figure 8. Circular map of C. hiranonis canine isolates. A) CH 1 and B) CH22. Chromosome tracks from outside to inside as follows. 
1) CDS Forward strand 2) CDS reverse strand CDS 3) GC content 4) Non CDS features 5) GC content 6) GC skew and 7) Genes of 
interest bile acid 7α-dehydratase (red), Choloylglycine hydrolase (blue).  
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Figure 9.   Heatmap of genes involved in bile acid metabolism present in the genome of 
C. hiranonis canine isolates (CH1 and CH22) when compared to the reference genome 
of DSM 13275.  Choloylglycine hydrolase is present in all the three genomes 
compared, while bile acid 7α- dehydratase was not detected in the genome of DSM 
13275.  
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Figure 10. A phylogenetic tree based on conserved proteins predicted from whole 
genome sequencing data of C. hiranonis canine isolates with related species C. 
scindens and C. sordelli. The canine isolates cluster closely to each other and are 
similar to the reference strain DSM 13275. 
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CHAPTER IV 
EXPLORING CORRELATIONS BETWEEN CLOSTRIDIUM HIRANONIS AND 
FECAL SECONDARY BILE ACIDS IN DOGS 
 
 
4.1 Overview 
  Bile acids (BAs) play a crucial role in modulating the gut microbiota, 
regulating the host physiology by acting as signaling molecules via their interaction 
with nuclear receptors. There is increasing evidence that BAs play a key role in 
maintaining gastrointestinal health and influence lipid, glucose, and energy metabolism 
in the host. The gut microbiota helps in maintaining a normal BA metabolism, size of 
the BA pool and regulates the enterohepatic circulation of BAs.  The relationship 
between microbiota and BAs is highly complex and interconnected. BAs may alter gut 
microbiota and vice versa. Therefore, an altered gut microbiota (dysbiosis) can alter the 
BA composition. The inter-play between gut bacteria and bile acids can impact host 
health and modulate the gut microbiota.  Enzymes produced by the gut microbiota, 
such as bile salt hydrolases (BSH) and dehydroxylases (HSDH) structurally modify 
primary bile acids (PBAs) synthesized by the host metabolic machinery to form 
secondary bile acids (SBAs). The BA biotransformation of PBAs to SBAs is limited to 
a narrow range of gut bacterial species. The level of SBAs in the host is regulated by 
the abundance of BA 7α-dehydroxylating gut bacteria like C. scindens and C. 
hiranonis.  
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BA 7α-dehydroxylation may thus be a crucial step in regulating host BA 
composition and an alteration in the abundance of BA 7α-dehydroxylating may lead to 
BA dysmetabolism. Therefore, the objective of this study was to explore the 
correlation between C. hiranonis and SBAs in canine feces. Fecal bile acids were 
measured by an in-house GC-MS assay and correlated to C. hiranonis Ct values (using 
a species-specific PCR). Furthermore, serum bile acids (SBA) data and C. hiranonis Ct 
values were added to previous 16S rRNA sequencing data from dogs with EPI, acute 
diarrhea, and chronic diarrhea and then analyzed. The results from this study suggest a 
significant association between C. hiranonis and secondary bile acid concentrations in 
fecal samples of dogs. The ROC analysis showed that the abundance of C. hiranonis 
can be used to discern between normal and low fecal secondary bile acids with a 
sensitivity of 88% and specificity of 90%. A significant clustering based on fecal SBAs 
and C. hiranonis was observed in dogs with EPI, and dogs with acute and chronic 
diarrhea following fecal microbiota transplantation.  
 
4.2 Introduction 
Microbiota and their metabolites play a regulatory role throughout the intestine 
and may correlate with histopathological severity [42, 173]. Furthermore, the 
microbiota is responsible for multiple metabolic functions, one of which includes 
metabolism and regulation of bile acids [54]. Bile acid production first occurs in the 
liver from cholesterol where the PBAs cholic acid and chenodeoxycholic are 
synthesized. PBAs are then conjugated with either taurine or glycine in the liver and 
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stored in the gallbladder [84]. Upon release of bile acids into the small intestine 
following a meal, their role includes nutrient digestion and solubilizing vitamins [174]. 
While the majority of enterohepatic absorption and recirculation of bile acids occurs in 
the terminal ileum, approximately 5% is excreted into the colon and deconjugated and 
dehydroxylated by colonic bacteria forming the secondary bile acids deoxycholic acid, 
lithocholic acid, and ursodeoxycholic acid [84, 175]. Thus, microbial dysbiosis 
identified in animals with gastrointestinal diseases may negatively affect gut 
homeostasis leading to bile acid dysmetabolism, especially if the abundance of some of 
the key bacterial species responsible for BA biotransformation is altered.  
 Studies in humans have suggested a role for bile acid dysmetabolism in gut 
inflammation [176, 177]. Findings from these studies show that secondary bile acids 
are decreased in feces of patients with IBD. Duboc et al. (2013), also describe a 
concurrent dysbiosis in patients with IBD and have shown in vitro experiments, which 
reflect decreased inflammatory response in the presence of deoxycholic acid. A 
collection of work in humans with diarrhea predominant irritable bowel syndrome 
(IBS-D) has identified an increase in fecal concentrations of primary bile acids, which 
affects approximately one-third of patients [96, 99, 178].  
Despite a growing body of information describing fecal bile acids in humans 
with chronic GI disease, studies investigating the role of bile acids in the feces of dogs 
are limited. Using an untargeted metabolomics approach, Honneffer et al.showed 
alterations in bile acid metabolism, tryptophan metabolism, and the pentose phosphate 
pathway in dogs with idiopathic IBD [110]. Preliminary work by Guard et al.showed 
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that fecal bile acid profiles became less dominated by primary bile acids and shifted to 
a higher proportion of secondary bile acids in dogs with IBD undergoing treatment 
when compared to the bile acid profiles at the time of initial diagnosis in these dogs. 
However, despite improvement in clinical activity scores, bacterial dysbiosis was 
present even after 8 weeks of treatment [111].  Altered bile acid profiles with a 
concurrent bacterial dysmetabolism were also demonstrated in dogs with naturally 
occurring diabetes mellitus. Diabetic dogs had increased primary bile acids and 
decreased levels of lithocholic acid in their feces. Bacterial groups such as 
Erysipelotrichia, Clostridia, and Bacteroidia were differentially abundant in the feces of 
healthy dogs when compared to dogs with diabetes [179].    
The aim of this study was to examine the correlation between C. hiranonis (a 
bile acid 7α-dehydroxylating bacterium) and secondary bile acids in fecal samples from 
healthy dogs and dogs with GI disease. Fecal bile acids were measured by an in-house 
GC-MS assay and correlated to C. hiranonis Ct values from a species-specific PCR. 
Furthermore, secondary bile acid data and C. hiranonis Ct values were analyzed 
together with 16S rRNA sequencing data from dogs with EPI, acute diarrhea, and 
chronic diarrhea. 
 
4.3 Materials and Methods  
4.3.1 Correlation of C. hiranonis with fecal secondary bile acids in dogs using 
species specific PCR        
 Fecal secondary bile acids concentrations and abundance of C. hiranonis by 
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qPCR from leftover fecal samples from previous studies were analyzed according to 
the methods described below to test the association between abundance of C. hiranonis 
and secondary bile acids in healthy dogs and dogs with GI disease. A total of 243 
samples were used for this analysis.  
 
4.3.2 Clostridium hiranonis quantitative PCR  
DNA was extracted from an aliquot of 100 mg from each canine fecal sample 
using the MoBio Power soil DNA isolation kit (MoBio Laboratories, CA) according to 
the manufacturer's instructions. The qPCR assays were performed using a species 
specific primer set Hirano F2 (5′- AGTAAGCTCCTGATACTGTCT-3′) and Hirano R 
(5′- AGGGAAAGAGGAGATT AGTCC--3′)  reported previously [168]. Briefly, 
qPCR reactions were performed using SYBR green-based reaction mixtures. The final 
total reaction volume was 10 μl. The final mix consisted of 5 μl SsoFast EvaGreen® 
supermix (Bio-Rad Laboratories, CA) 0.4 μl each of a forward and reverse primer 
(final concentration: 400 nM), 2.6 μl of PCR water and 2 μl of normalized DNA (final 
concentration: 5 ng/μl). The PCR conditions for PCR were as follows: initial 
denaturation at 98°C for 2 min, then 40 cycles with denaturation at 98°C for 3 s and 
annealing for 3 s at 50 °C. Melt curve analysis was performed post-amplification using 
these conditions: 95°C for 1 min, 55°C for 1 min and increasing incremental steps of 
0.5°C for 80 cycles for 5 s each. All samples were run in duplicate fashion. The qPCR 
data were expressed as threshold-cycle (Ct) as an estimate of bacterial burden. 
 To test the specificity of the used primers, 16S rRNA gene clone libraries were 
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constructed from the PCR amplicons as described previously [141, 180]. The PCR 
amplicons were ligated into pCR4-TOPOs vectors and transformed into competent 
Escherichia coli (DH5α)- by heat shock following the manufacturer's instructions 
(Invitrogen, CA). For the primer set, 20 clones were picked, plasmids were purified 
and the amplified sequence was sent for Sanger sequencing at Eton Biosciences (San 
Diego, CA). 
 
4.3.3 Canine fecal bile acid measurement 
An in-house assay for measuring unconjugated fecal bile acids using a gas 
chromatography-mass spectrometry (GC-MS) targeting cholic acid (CA), 
chenodeoxycholic acid (CDCA), lithocholic acid (LCA), deoxycholic acid (DCA), and 
ursodeoxycholic acid (UDCA) as described previously was used to measure the bile 
acids [181]. Primary and secondary bile acids were presented as µg/mg of lyophilized 
fecal content in addition to being expressed as a percent of the total bile acid pool. The 
primary bile acids (cholic acid and chenodeoxycholic acid) were combined with 
secondary bile acids (lithocholic acid, deoxycholic acid, and ursodeoxycholic acid) to 
represent total fecal bile acids measured. Secondary bile acids for the purpose of the 
analysis in this chapter were expressed as a percentage of total fecal bile acids 
measured. 
Fecal bile acid concentrations in dogs with EPI, acute and chronic diarrhea 
were measured using an in-house GC-MS assay.  As mentioned previously, secondary 
bile acid concentrations were expressed as a percentage of total bile acids in the 
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sample. The samples were categorized as having a normal or decreased fecal bile acid 
concentration, with normal defined as having ≥50% of secondary bile acid (% of total) 
and decreased being <50% of secondary bile acid (% of total) 
 
4.3.4 Microbiota and Secondary bile acids in dogs with gastrointestinal disease 
4.3.4.1 16S rRNA sequencing datasets 
Three 16S rRNA sequencing datasets which had left over fecal samples for 
measuring fecal bile acids were chosen and prospectively analyzed.  
The datasets used were 
1. Fecal microbiome of dogs with exocrine pancreatic insufficiency (EPI) (described 
in chapter 2). Dogs with EPI not enzyme supplemented (EPI-E) n= 5; Dogs with 
EPI on enzyme supplementation (EPI+E) n= 17; and healthy dogs (n=18)  
2. Fecal microbiome of dogs with chronic diarrhea that underwent fecal microbiota 
transplantation (n=14). 
3. Fecal microbiome of dogs with acute diarrhea that underwent fecal microbiota 
transplantation (n=10).  
4.3.4.2 Data processing        
 Sequences from the above datasets were processed and analyzed using 
Quantitative Insights Into Microbial Ecology (QIIME) v1.8 [116, 117] as previously 
described in chapter 2 [137]. In brief, the sequencing data from each study was 
processed individually. The sequence data was demultiplexed, and then quality filtered 
using the default settings for QIIME. Chimeras were detected and filtered out and the 
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remaining sequences were clustered into Operational Taxonomic Units (OTUs) by 
using an open reference approach in QIIME [117]. Taxonomy was assigned to 
representative sequences using the default parameters in QIIME. Sequences assigned 
as chloroplast, mitochondria, unassigned and low abundance OTUs, containing less 
than 0.01% of the total reads in the dataset were removed [120].  
Secondary bile acids were measured as described above and secondary bile acid 
concentrations were expressed as a percentage of total bile acids in the sample. The 
animals were categorized as having a normal (cut off of ≥ 50%) and decreased (<50%) 
secondary bile acid concentration in feces and was added as additional metadata to the 
mapping files.  
Species-specific PCR was performed as mentioned above. The metric used for 
analyzing the presence/absence of C. hiranonis in the fecal samples with the species-
specific qPCR was cycles to cross threshold (Ct) and was indirectly used as a measure 
of bacterial burden. A higher bacterial load will result in a lower time to cross the 
threshold and will result in a lower Ct value. A Ct value higher than 30 was considered 
to be negative for C. hiranonis and less than 30 was considered to be positive for C. 
hiranonis. The presence or absence of C. hiranonis was then added as additional 
metadata to the mapping files.  
Beta diversity was evaluated with the phylogeny based UniFrac distance [121] 
metric and visualized using Principal Coordinate Analysis (PCoA) plots with the 
workflow script beta_diversity_through_plots.py in QIIME. 
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4.3.4.3 Statistical analysis 
Data was tested for normality using a Shaprio Wilk’s test.  Receiver operating 
curves (ROC) were constructed and the area under the curve (AUC) was calculated to 
assess the appropriate cut off-point. A ROC curve allows for visualizing the reciprocal 
relationship between sensitivity (true positive fraction) and specificity (false positive 
fraction).  AUC is a value of diagnostic accuracy that quantifies the overall ability of 
the test to discriminate between control (normal secondary bile acid %) and test 
(decreased secondary bile acid %). AUC ranges from non-informative (AUC = 0.5) to 
a test with perfect accuracy (AUC = 1) [182-184]. P <0.05 was considered as 
statistically significant. Statistical analysis was performed using GraphPad Prism 
v.5.04 (GraphPad Software Inc., San Diego, CA).  
Analysis of Similarity (ANOSIM) test within PRIMER 6 software package 
(PRIMER-E Ltd., Luton, UK) was used to analyze if the clustering of microbial 
communities based on normal and decreased secondary bile acids was statistically 
significant in the 16S rRNA sequencing datasets. 
 
4.4 Results 
4.4.1 Correlation between abundance of C. hiranonis and bile acid metabolism using 
species-specific qPCR 
Clostridium hiranonis (Ct values) negatively correlated with secondary bile 
acids when expressed as a percentage of total fecal bile acids (Spearman ρ = -0.57; 
P<0.001) as shown in (Figure 11). The fecal concentrations of lithocholic acid, 
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deoxycholic acid, and total secondary bile acids, expressed as µg/mg of lyophilized 
fecal content, also negatively correlated with the abundance of C. hiranonis (Ct 
values). There was no correlation between ursodeoxycholic acid concentrations and C. 
hiranonis (Ct values) (Table 10). 
ROC curves were generated and the AUC was calculated to assess the utility of 
C. hiranonis as a predictor for the percentage of fecal secondary bile acids in feces. 
With a Ct value of 30, C. hiranonis can be used to discern between normal and low 
fecal secondary bile acids (with a normal defined as ≥ 50%) with a sensitivity of 88% 
and specificity of 90% in dogs (Figure 12). 
 
4.4.2 Secondary bile acids and C. hiranonis in dogs with gastrointestinal disease
 There was a significant separation between the dogs with normal and decreased 
fecal secondary bile acids (as a % of total fecal bile acids) with a cut off of ≥50% of 
secondary bile acids considered as normal in all the three 16S rRNA sequencing 
datasets. ANOSIM test showed a significant difference in microbial communities 
between dogs with a normal bile acid metabolism and decreased fecal secondary bile 
acids in dogs with EPI (R= 0.56, P =0.001) (Figure 14, Panel B), acute diarrhea (R= 
0.56, P =0.001) (Figure 15, Panel B), and chronic diarrhea (R= 0.13, P =0.001) (Figure 
16, Panel B). 
PCoA plots showed a clustering pattern on the presence/absence of C. 
hiranonis, with a cut off of a Ct value of 30 considered as C. hiranonis being present in 
all the three 16S rRNA sequencing datasets. ANOSIM test showed a significant 
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difference in microbial communities between dogs and presence or absence of C. 
hiranonis in dogs with EPI (R= 0.56, P =0.001) (Figure 16, Panel B), acute diarrhea 
(R= 0.42; P =0.001) (Figure 17, Panel B), and chronic diarrhea (R= 0.141, P =0.001) 
(Figure 18, Panel B) 
 
4.5 Discussion 
 The regulation of BA homeostasis in mammals is a complex process regulated 
via extensive cross-talk between liver, intestine, and intestinal microbiota. The balance 
between gut microbiota and bile acid pool/composition is necessary for maintaining 
host GI health. The interactions of BAs with the intestinal microbiota to maintain a bile 
acid homeostasis and perturbation of this balance can affect many host physiological 
functions [90, 91]. 
 This study evaluated the correlation between the bile acid 7α-dehydroxylating 
bacterium, C. hiranonis and fecal secondary bile acids in healthy dogs and dogs with 
GI disease. The results from this study suggest a significant association between C. 
hiranonis and secondary bile acid concentrations. The ROC analysis showed that the 
abundance of C. hiranonis can be used to discern between normal and low fecal 
secondary bile acids with a sensitivity of 88% and specificity of 90% in dogs. 
In humans, IBS is a GI disorder that has a complex pathophysiology and is 
generally classified based on the symptoms as diarrhea predominant (IBS-D) or 
constipation predominant (IBS-C). In humans, approximately 30% of patients with 
IBS-D have BA malabsorption (BAM) [92, 93]. An increased proportion of primary 
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BAs in the feces of IBS-D patients compared with healthy control subjects has been 
reported previously [94, 95]. Duboc et al.reported higher concentrations of conjugated 
bile acids and lower concentartions of secondary bile acids in feces and an associated 
impairment in deconjugation and transformation activities of the microbiota in IBD 
patients [96]. 
Given the prevalence of bile acid malabsorption in human chronic diarrhea 
patients, Kent et al. hypothesized that bile acid malabsorption may be a relevant 
disorder in dogs [185]. Their study analyzed C4 concentrations in 17 dogs with chronic 
diarrhea and 20 healthy control dogs and found no significant difference between 
control dogs and dogs with chronic diarrhea.  
In this study, we further observed a significant clustering based on fecal 
secondary bile acids and C. hiranonis in dogs with EPI, and dogs acute and chronic 
diarrhea following fecal microbiota transplantation. The utility of fecal secondary bile 
acids and C. hiranonis to predict the response to an intervention such as fecal 
microbiota transplantation needs to be explored. 
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Table 10: Correlations between Ct values of C. hiranonis and secondary bile 
acids in fecal samples  
 Pearson's Spearman's 
 R P ρ P 
Total Secondary BA ug/mg  -0.3339 < 0.0001 -0.5717 < 0.0001 
Secondary BA (% of total) -0.7349 < 0.0001 -0.5689 < 0.0001 
Lithocholic Acid (% of total) -0.4151 < 0.0001 -0.7 < 0.0001 
Deoxycholic Acid (% of total) -0.407 < 0.0001 -0.5192 < 0.0001 
Ursodeoxycholic Acid (% of total) 0.0848 0.1886 0.04105 0.5251 
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Figure 11:  Correlation of fecal C. hiranonis (Ct values) and fecal secondary bile acids 
(expressed as a % of total fecal bile acids) in healthy dogs and dogs with 
gastrointestinal disease. The Spearman’s rank correlation shows a significant 
correlation between fecal C. hiranonis (Ct values) and fecal secondary bile acid (% of 
total fecal bile acids) (ρ =-0.56, P<0.001). Dashed lines represent the 95% confidence 
interval for the predicted values (data based on fecal samples of 243 dogs). 
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Figure 12. Receiver operating characteristic (ROC) curve for C. hiranonis (Ct values) 
and normal secondary bile acids in fecal samples from dogs. ROC curve analyses 
evaluated the sensitivity and specificity of C. hiranonis qPCR to detect normal 
secondary bile acids. Normal secondary bile acids were defined as ≥ 50% of secondary 
bile acids (when expressed as a percentage of total fecal bile acids).
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Figure 13. Principal coordinates analysis (PCoA) of microbial communities from the fecal samples of healthy dogs, dogs with 
EPI were treated and untreated) based on fecal secondary bile acids. The figure shows a 3D PCoA plot based on A) clustering 
based on disease status B) clustering based on secondary bile acid (as a % of total). Analysis of similarity (ANOSIM) revealed 
clustering between the groups (P = 0.001). Normal: ≥50% of secondary bile acids; decreased: <50% of secondary bile acids.
 87 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Principal coordinates analysis (PCoA) of microbial communities from the fecal samples of dogs with acute diarrhea, 
that underwent FMT, based on fecal secondary bile acids. The figure shows a 3D PCoA plot based on A) clustering based on 
FMT time point B) clustering based on secondary bile acids (as a % of total). Analysis of similarity (ANOSIM) revealed a 
clustering based on fecal secondary bile acids (P=0.001). Normal: ≥50% of secondary bile acids; decreased: <50% of 
secondary bile acids 
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Figure 15. Principal coordinates analysis (PCoA) of microbial communities from fecal samples of dogs with chronic diarrhea, 
that underwent FMT based on fecal secondary bile acids. The figure shows a 3D PCoA plot based on A) clustering based on 
FMT time point B) clustering based on secondary bile acids (as a % of total). Analysis of similarity (ANOSIM) revealed a 
clustering based on fecal secondary bile acids (P=0.001). Normal: ≥50% of secondary bile acids; decreased: <50% of 
secondary bile acids 
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Figure 16. Principal coordinates analysis (PCoA) of microbial communities from the fecal samples of healthy dogs, dogs with 
EPI that were treated and untreated, based on presence or absence of C. hiranonis. The figure shows a 3D PCoA plot based on 
A) clustering based on disease status B) clustering based on C. hiranonis (Ct values). Analysis of similarity (ANOSIM) 
revealed based on the presence or absence of C. hiranonis (P = 0.001).  
Present: ≤ 30 Ct; absent >30 Ct. 
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Figure 17. Principal coordinates analysis (PCoA) of microbial communities from fecal samples of dogs with acute diarrhea that 
underwent FMT, based on the presence or absence of C. hiranonis. The figure shows a 3D PCoA plot based on A) clustering 
based on FMT time point B) clustering based on secondary C. hiranonis (Ct values). Analysis of similarity (ANOSIM) 
revealed clustering based on the presence or absence of C. hiranonis. (P=0.001). Present: ≤ 30 Ct; absent > 30 Ct. 
 91 
 
 
Figure 18. Principal coordinates analysis (PCoA) of microbial communities from fecal samples of dogs with chronic diarrhea 
that underwent FMT, based on the presence or absence of C. hiranonis. The figure shows a 3D PCoA plot based on A) 
clustering based on FMT time point B) clustering based on C. hiranonis. (Ct values). Analysis of similarity (ANOSIM) 
revealed clustering based on clustering based on the presence or absence of C. hiranonis. (P=0.001). Present: ≤ 30 Ct; absent > 
30 Ct.
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CHAPTER V 
SUMMARY AND CONCLUSIONS 
 
Bile acids are versatile metabolites that can act as signaling molecules and thereby exert 
diverse endocrine and metabolic actions by activating bile acid receptors such as FXR and 
TGR5. Regulation of bile acid homeostasis in mammals is complex and is regulated via 
extensive cross-talk between the liver, intestine, and gut microbiota. 
A dysbiotic microbiota will impair bile acid metabolism, alter gastrointestinal barrier 
function, can activate inflammatory signaling pathways, leading to an altered activation of bile 
acid receptors, and can influence gene expression involved in various metabolic processes, i.e. 
glucose homeostasis, insulin resistance, and obesity. These observations highlight the importance 
of a balanced intestinal bacterial microbiota. The function of the gut microbiota to transform bile 
acids may be of pivotal importance to maintain bile acid signaling and energy homeostasis, and 
thereby to maintain host health. 
 
5.1 Summary 
The aim of this study was to isolate and characterize C. hiranonis from canine feces. We 
were able to isolate two strains of C. hiranonis from canine feces. The isolates were very similar 
to each other, and phylogenetic trees based on fatty acid methyl ester analysis and whole genome 
sequencing indicate that these isolates are related to the human isolate C. hiranonis DSM 13257, 
but may be different subspecies.  Whole genome sequencing was able to detect the genes for the 
presence of bile acid converting enzymes choloylglycine hydrolase (EC 3.5.1.24) and gene 
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encoding bile acid 7α-dehydratase (EC 4.2.1.106). This further reaffirms previous findings that 
this bacterium is a bile acid 7α-dehydroxylating species.  
 We also explored the correlation between the abundance of C. hiranonis and fecal 
secondary bile acids in dogs. We were able to find a significant correlation between secondary 
bile acid concentrations and C. hiranonis, using both relative abundances of C. hiranonis from 
16SrRNA sequencing datasets and species-specific qPCR in canine feces. 
 The major limitations of this study are the lack of in vitro and in vivo experiments to 
demonstrate the ability of the canine C. hiranonis isolates to convert primary bile acids in vitro 
and in vivo. 
 
5.2 Future directions 
This study identified that C. hiranonis is linked to bile acid metabolism in dogs. Further 
research will be needed to confirm and strengthen the results obtained. The ability of the isolated 
strains to convert primary bile acids into secondary bile acids has to be assessed in vitro and in 
vivo, and ultimately the possibility for one day using C. hiranonis as probiotics for correcting 
fecal bile acid dysmetabolism in dogs. In vitro and functional tests to understand the role of C. 
hiranonis in modulating gut microbiota and bile acids needs to be done. 
To further understand the link between gut microbiota, bile acid metabolism, and 
gastrointestinal disease in companion animals, large-scale metagenomic sequencing studies in 
both healthy and diseased populations should be conducted to understand the bacterial 
community composition. Specific microbial fingerprints may be able to reliably predict disease 
risk or treatment success (for e.g., the success of FMT).  
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Furthermore, exploring the colonization of germ free mice with C. hiranonis for different 
durations and monitoring the bile acid pool in various segments in the gastrointestinal tract over 
time may provide information if other bacterial populations are needed for C. hiranonis to 
convert PBAs to SBAs. 
To comprehend the functional metabolic interactions between gut microbiota and the host 
for maintaining normal bile acid metabolism, utilizing tools such as metatranscriptomics, 
metaproteomics and metabolomics could provide information on genetic potential, transcripts, 
proteins, and metabolites. However, changes in the expression of transcription factors and/or 
abundance of metabolic enzymes may not always truly reflect the actual metabolic pathways 
taking place in the host. Therefore, in vivo experiments would be critical to obtain a complete 
physiological picture. 
 
5.3 Conclusions 
 In conclusion, the abundance of C. hiranonis is altered in the feces of dogs with 
gastrointestinal diseases. Furthermore, this study was also able to find a significant correlation 
between secondary bile acid concentrations and abundance of C. hiranonis in canine feces. 
Further studies are required to determine the ability of the canine C. hiranonis isolates to convert 
primary bile acids into secondary bile acids both in vitro and in vivo, and its application as a 
potential probiotic for correcting bile acid dysmetabolism in dogs. 
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